


Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories

Graphical abstract



Authors

Jeanette A.I. Johnson, Daniel R. Bergman, Heber L. Rocha, ..., Genevieve L. Stein-O'Brien, Elana J. Fertig, Paul Macklin

Correspondence

gsteinobrien@jmhi.edu (G.L.S.-O.),
ejfertig@som.umaryland.edu (E.J.F.),
macklinp@iu.edu (P.M.)

In brief

We developed a plain text modeling language—a cell behavior hypothesis grammar—to easily build virtual cell models and connect them to data, helping scientists to unlock the hidden dynamics of tissues. We provide examples showing how to use them in virtual experiments exploring how cancer responds to the cells in its environment and how the brain forms layers in development.

Highlights

- Democratize computing by encoding complex multicellular dynamics in plain language
- Framework digitizes tumor microenvironment dynamics, neurodevelopment, and more
- Personalize, parameterize, and validate virtual cell lab experiments using multi omics
- *In silico* hypothesis testing links theory to data accelerating biological discovery

Theory

Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories

Jeanette A.I. Johnson,^{1,2,4,5,34} Daniel R. Bergman,^{1,2,3,4,5,6,34} Heber L. Rocha,⁷ David L. Zhou,⁸ Eric Cramer,⁹ Ian C. Mclean,⁹ Yoseph W. Dance,^{10,11} Max Booth,¹ Zachary Nicholas,^{8,12} Tamara Lopez-Vidal,¹ Atul Deshpande,^{1,2,13,14} Randy Heiland,⁷ Elmar Bucher,⁷ Fatemeh Shojaeian,¹⁵ Matthew Dunworth,¹⁶ André Forjaz,¹⁷ Michael Getz,⁷ Inês Godet,¹⁸ Furkan Kurtoglu,⁷ Melissa Lyman,^{1,2} John Metzcar,^{7,19} Jacob T. Mitchell,^{1,2,12} Andrew Raddatz,²⁰ Jacobo Solorzano,²¹ Aneequa Sundus,⁷ Yafei Wang,⁷ David G. DeNardo,²² Andrew J. Ewald,^{1,2,16,23} Daniele M. Gilkes,^{1,11,17}

(Author list continued on next page)

¹Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

²Convergence Institute, Johns Hopkins University, Baltimore, MD, USA

³Department of Pharmacology, Physiology, and Drug Development, University of Maryland School of Medicine, Baltimore, MD, USA

⁴Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA

⁵Marlene & Stuart Greenbaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

⁶University of Maryland Institute of Health Computing, University of Maryland School of Medicine, Baltimore, MD, USA

⁷Department of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA

⁸Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA

⁹Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA

¹⁰Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA

¹¹Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA

¹²Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA

¹³Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, USA

¹⁴Data Science and AI Institute, Johns Hopkins University, Baltimore, MD, USA

¹⁵Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

¹⁶Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

¹⁷Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA

¹⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA

¹⁹Department of Informatics, Indiana University, Bloomington, IN, USA

(Affiliations continued on next page)

SUMMARY

Cells interact as dynamically evolving ecosystems. While recent single-cell and spatial multi-omics technologies quantify individual cell characteristics, predicting their evolution requires mathematical modeling. We propose a conceptual framework—a cell behavior hypothesis grammar—that uses natural language statements (cell rules) to create mathematical models. This enables systematic integration of biological knowledge and multi-omics data to generate *in silico* models, enabling virtual “thought experiments” that test and expand our understanding of multicellular systems and generate new testable hypotheses. This paper motivates and describes the grammar, offers a reference implementation, and demonstrates its use in developing both *de novo* mechanistic models and those informed by multi-omics data. We show its potential through examples in cancer and its broader applicability in simulating brain development. This approach bridges biological, clinical, and systems biology research for mathematical modeling at scale, allowing the community to predict emergent multicellular behavior.

INTRODUCTION

Generating temporally resolved multicellular predictions remains an open computational challenge.^{1–3} Bioinformatics techniques and machine learning can predict cellular trajectories and dynamic phenotypic changes in individual cell types from snapshots in single-cell assays,^{4–6} but they cannot account for

more complex temporal changes throughout multicellular ecosystems. More advanced computational tools are needed to fill the gaps between measurement times and leverage biological knowledge and mechanism to forecast unseen emergent behaviors in multicellular systems *de novo*. Mechanistic mathematical modeling can extend static high-resolution data to multicellular dynamics. Agent-based modeling is a powerful mathematical

Luciane T. Kagohara,^{1,2} Ashley L. Kiemen,^{1,2,15} Elizabeth D. Thompson,¹⁵ Denis Wirtz,^{1,2,11,15,17,24} Laura D. Wood,^{1,15} Pei-Hsun Wu,^{2,11,17} Neeha Zaidi,^{1,2} Lei Zheng,^{1,2,25,26} Jacquelyn W. Zimmerman,^{1,2} Jude M. Phillip,^{1,10,11,17,27} Elizabeth M. Jaffee,^{1,2} Joe W. Gray,^{9,28} Lisa M. Coussens,^{28,29} Young Hwan Chang,^{9,28} Laura M. Heiser,^{9,28} Genevieve L. Stein-O'Brien,^{1,2,8,12,14,30,31,*} Elana J. Fertig,^{1,2,4,5,6,10,14,32,33,*} and Paul Macklin^{7,35,*}

²⁰Department of Biomedical Engineering, Georgia Institute of Technology, Emory University, Atlanta, GA, USA

²¹Centre de Recherches en Cancerologie de Toulouse, Toulouse, France

²²Department of Medicine, Washington University Saint Louis, St. Louis, MO, USA

²³Giovannis Institute for Translational Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

²⁴Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA

²⁵Mays Cancer Center, University of Texas Health, San Antonio, TX, USA

²⁶MD Anderson Cancer Center, San Antonio, TX, USA

²⁷Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

²⁸Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

²⁹Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA

³⁰Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

³¹Kavli Neuroscience Discovery Institute, Johns Hopkins University, Baltimore, MD, USA

³²Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD, USA

³³Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

³⁴These authors contributed equally

³⁵Lead contact

*Correspondence: gsteinobrien@jmh.edu (G.L.S.-O.), ejfertig@som.umaryland.edu (E.J.F.), macklinp@iu.edu (P.M.)
<https://doi.org/10.1016/j.cell.2025.06.048>

modeling technique to predict emergent complex behaviors from populations of individual software agents that follow predefined rules based on their identity, state, and nearby conditions.⁷ Over a series of simulation time increments, each agent calculates its next action by evaluating its surroundings and internal state variables to calculate its next action. Agent-based models (ABMs) are well suited to studying the dynamics of multicellular biology, as each agent can encode a cell based on its state, type, and associated rules of behavior, including their actions upon or in response to nearby cells (i.e., cell-cell interactions).^{8–11} By encoding the rules of multicellular systems, ABMs empower *in silico* experimentation and modeling of cellular dynamics, even in the absence of temporal measurements.^{9,12} ABMs have been used as powerful *in silico* models to test hypotheses in human development and disease where comprehensive experimentation is not possible.^{13–28} By predicting the future state of cells and the impact of perturbations, ABMs provide a powerful toolset to generate digital twins and virtual clinical trials.^{3,10,29–38} Furthermore, the ability to run ABM simulations at scale across diverse biological conditions^{38–40} can refine biological understanding and predict future cellular behaviors in these complex systems. Altogether, these *in silico* models can prioritize bench experiments or clinical trials, addressing the costs and practical constraints of real-world experimentation.

While powerful, mathematical modeling lacks the language to directly connect to the vast accumulated knowledge of the biological community and to easily transform data into equations. As a result, widespread application of ABMs for modeling biological systems is currently limited both by the highly technical nature of most software implementations and the ability to integrate molecular data to ground simulations in the real world. The former issue gatekeeps ABMs away from those without significant computational experience, limiting widespread application and even posing a barrier for many potential users with extensive knowledge of the biological systems already en-

coded in ABMs. Even for advanced computational users, the custom coding required can limit reproducibility. Software implementing ABMs has been developed to overcome these limitations.^{41–50} Still, disease etiology and operating biological hypotheses are often hidden deep in source code, obscuring the assumptions about the system and the full set of hypotheses being simulated. These technical challenges to ABMs also limit the ability to embed molecular datasets, which are often too high-dimensional to manually encode into equations of agents and rules. A conceptual framing that can abstract cellular phenotypes and their interactions—combined with a simplifying coding infrastructure—is essential for the integration of molecular measurements to personalize model predictions. Facilitating *in silico* modeling requires both an intuitive language—to concisely express expert knowledge as plain text descriptions of the rules of cell interactions that “encode” a system—and also software to translate these plain text descriptions into mathematical expressions and executable models for immediate exploration of a digitized copy of the biological system.⁴⁷

To enable human-interpretable construction of ABMs, we developed a cell behavior hypothesis grammar that bridges the divide between biology and mathematical modeling, by embracing well-defined human language hypotheses on cell behavior as a logical model that can be translated directly into the language of mathematical equations in an ABM. This one-for-one relationship between human language and mathematics allows us to systematically curate and integrate biological knowledge and high-throughput data to make biology *computable*.⁵¹ Briefly, our grammar defines the components of ABMs based on labeled cell types and behaviors. Rules can be both knowledge driven (e.g., expert statements drawing from literature and prior training) or data driven (directly measured from experimental data). This in turn enables virtual “thought experiments”⁵² that challenge and extend our understanding of multicellular systems and that generate new testable hypotheses.




Figure 1. Using agent-based models to digitize cell knowledge

(A) Agent-based models (ABMs) simulate cells as individual objects with separate states and processes.

(B) Cell agents use rules that process biophysical signals in their microenvironment—including other cells—to drive changes in their behaviors. These rules are based on our biological hypotheses.

(C) The cell behavior grammar combines signals and behaviors from well-defined dictionaries (1 and 2) to create interpretable hypothesis statements (3), which can be automatically transformed into mathematical models (4) for use in computer models.

Thus, the grammar allows for broad application of ABMs in a reproducible, modular, and extensible manner. We demonstrate how this grammar's reliance on annotated cellular states enables both encoding of expert-curated biological knowledge as well as high-throughput molecular profiling data, applying these techniques to sample models in cancer biology. These examples are progressively more complex and designed to span tumor cell growth, invasion, and response to immunotherapy. We then extend this grammar to a further example simulating brain development with models parameterized from spatial transcriptomics (ST) data in the Allen Brain Atlas,⁵³ showing the broad applicability of our hypothesis grammar to biological systems beyond cancer. The cases embedding multi-omics and spatial molecular data enabled by this grammar demonstrate how to ground simulations in data to form more accurate digital models of multicellular dynamics.

RESULTS

A grammar encoding cell behavioral responses to extracellular signals

In this paper, we implement our new hypothesis grammar for ABMs in the well-calibrated, robust agent-based modeling ecosystem of PhysiCell.⁴⁷ ABM frameworks⁸ like PhysiCell⁴⁷ model individual cells as software agents with independent states (e.g., position, cycle status) and processes (e.g., motility, secretion); see Figure 1A. Each cell agent responds to stimuli (signals) in their microenvironment, which effect changes in their behaviors (Figure 1B). Previous implementations of PhysiCell were limited to pre-defined models and interactions or required users to have expert knowledge across the diverse domains of biology, mathematics, and computer science to hand-code models with customized

cellular agents, stimuli, and interactions. Here, we simplify this encoding by expanding the PhysiCell software to encode the agents and stimuli as human-readable sentences that are then parsed into ABMs. Briefly, this abstraction is enabled by writing cell hypotheses relating cell behavioral responses to signals in a grammar that can be translated into mathematics and executable code, as summarized below (e.g., typical rule in Figure 1C) and in detail in STAR Methods and Methods S1. In this hypothesis grammar, cellular behaviors and stimuli are expressed as nouns and their regulatory relationships as verbs, and parameters quantify these relationships. Hypotheses can be drawn from a variety of sources, including domain expertise, mining of prior literature, and analysis of transcriptomic and other data. Due to our uniform knowledge representation, all these rules can be compatibly integrated (Figures S1, S2, and S3) in mathematical models. Moreover, the use of plain language for cellular phenotypes also facilitates the direct mapping of ABM variables to the cellular labels inferred in analyses of single-cell and spatial multi-omics datasets.

In addition to the stimuli and cell types in the grammar and optional initial conditions provided from high-throughput molecular datasets, cellular behaviors simulated from ABMs also depend on both the parameters for the equations in these rules and the initial conditions of cellular phenotypes. While we implement the grammar using the PhysiCell agent-based modeling framework⁴⁷ as a reference implementation, it can be translated to other agent-based modeling systems.^{41,43–46,48–50} Still, an advantage of building this hypothesis grammar on top of PhysiCell is that it enables us to use a broad set of biochemical and biophysical parameters, which has been previously quantified and experimentally validated in the extensive literature and community-based development using this modeling framework.⁴⁷

The hypothesis grammar parses numeric variables for model parameters. Ideally, these parameters would be inferred from the literature or quantified from experimental data of the biological systems they seek to model. Parameter selection is a critical aspect of ABMs, as it can significantly affect simulation outcomes. While many parameters can be estimated experimentally or from the literature, the cellular and molecular heterogeneity of biological systems can differ between individuals and contexts. Throughout the development of PhysiCell, we have refined parameter selection processes in several ways (e.g., Bayesian approaches,⁵⁴ large-scale parameter space sweeps,^{38–40} and community-developed tools⁵⁵), laying the foundation for our hypothesis-based grammar and community-based outreach. Performing parameter sensitivity analysis remains a fundamental step in evaluating model performance. Prior to the grammar, implementing parameter sensitivity analyses generally required custom code to alter each model variable. We extend our software to include a graphical tool⁵⁶ for exploring and tuning parameters of rules governing signals and behaviors to simplify *in silico* parameter exploration. Additionally, we created software for analysis across the entire input space of models (parameters, initial conditions, and hypotheses; see Methods S1). This additional software module⁵⁷ is focused on *in silico* perturbations of parameters to test their sensitivity on model behavior.

Order-of-magnitude parameter estimates robustly predict qualitative behaviors of oxygen-dependent tumor cell proliferation, with greatest sensitivity to cell motility

In cancer, cell proliferation becomes unchecked, exhausting oxygen and nutrients in non-vascularized tumors. Modeling resource consumption provides a foundation for mathematical modeling of tumors, and this serves as the base example of tumor cell behavior in the absence of an immune response, from which other modeling examples are built.^{47,54,58–64} Following prior work developing a custom mathematical model of this system,⁵⁴ we now adapt our hypothesis grammar to model hypoxia-induced migration, where low oxygen conditions can “reprogram” tumor cells to a transient, post-hypoxic phenotype of increased chemotactic migration and where subsequent prolonged exposure to non-hypoxic conditions can “revert” those cells back to a less motile phenotype (Figure 2A). The language encodes these cell behaviors by using the language “oxygen decreases necrosis” and “oxygen decreases transformation to motile tumor cells.”

We used these rules to simulate 5 days of growth of a 2D tumor in an environment of 38 mmHg oxygenation (physioxia⁶⁵), starting from 2,000 viable cells seeded randomly in a virtual disk with a 400- μ m radius (Figure 2B). The ABM generated from these rules simulates a virtual tumor with an oxygen-poor necrotic core, while hypoxic cells disseminate throughout the virtual tumor with increasing frequency near the peri-necrotic boundary. Here, we observe an *in silico* model of a transient post-hypoxic phenotype of increased chemotactic migration, where cells eventually return to their baseline phenotype upon reoxygenation. Consistent with prior modeling predictions and experimental validation,^{54,66} these motile cells form invasive “plumes” in non-hypoxic tumor regions, but they can fail to exit the tumor and invade the surrounding tissue when their hypoxic adaptations do not persist in higher oxygen conditions (Figure 2B).

In this model, we selected parameters from our prior calibration of this model from literature-derived parameters and experimental validation to simulate the dynamics of an MDA-MB-231-derived orthotopic murine breast tumor model.^{54,66} We investigated the sensitivity of the model results to the parameter values, by computing the impact of varying parameter variations by 1% to 20% on key quantities of interest (QoIs). We assessed population growth by analyzing the area under curve (AUC) of non-motile and motile tumor cell populations and evaluated the differences in the radial distribution between live motile and non-motile cells (Figure 2C). The median values of the QoIs remained relatively stable across different perturbation levels in parameter space, indicating that the overall model behavior was not strongly influenced by small changes in these parameters. The variability of these outputs increased with higher perturbation levels, suggesting that while average behavior might be robust, individual simulations could exhibit greater variation (Figure 2D). Although individual simulation replicates showed variability consistent with the stochastic nature of tumor growth, key qualitative behaviors—such as the emergence of necrotic cores and the spatial gradients of cell proliferation and migration—were consistently observed across multiple replicates (Figure S4; Methods S1). This finding aligns with our recent




Figure 2. The hypoxia model captures the post-hypoxic dynamics

(A) Schematic of the tumor hypoxia model. Initially, the tumor is homogeneous without immune infiltration.

(B) Simulation of tumor hypoxia dynamics over 5 days, using reference parameters. (Bar: 400 μm .)

(C) Metrics extracted from the simulation, including area under the curve (AUC) for cell populations over 5 days, the radial distribution of live non-motile and live motile tumor cells at endpoint, and the Wasserstein distance of these distributions.

(D) Variation of quantities of interest (QoIs) under multiplicative perturbations in the 24D parameter space.

(E) Mean and standard deviation of the sensitivity index for each parameter across all QoIs. Model rules are enumerated in the order of their insertion. Each rule includes parameters representing the base behavior (base), saturation level (sat), half-max signal value (hfm), and hill power (hp). Parameters such as *rule3_hfm* and *rule7_hfm* denote the oxygen half-max values that trigger necrosis in non-motile and motile cells, respectively. Similarly, *rule8_hfm* and *rule4_hfm* represent the oxygen half-max values for phenotype transitions between motile and non-motile cells. A full description of all parameters can be found in [Methods S1](#).


large-scale investigation of highly stochastic tumor-immune ABMs,³⁸ which found that the outcome of individual simulation replicates can vary widely, while large sets of replicates can remain concordant.

Perturbations to the base values of the rules did not lead to significant changes in the QoIs. Half-max values—particularly those associated with necrosis onset and transitions between motile and non-motile phenotypes—significantly influenced both the magnitude and timing of tumor growth and the spatial distributions of cell populations (Figure 2E). These findings underscore

the importance of careful parameter estimation and rigorous sensitivity analysis in the application of ABMs, emphasizing the need for experimental quantification of the contribution of individual parameters to emergent behaviors in tumors.³⁸

Rules simulating fibroblast and neoplastic cells in pancreatic cancer demonstrate that fibroblasts promote invasion and physically block progression

In contrast to the hypoxia-derived tumor progression in our previous model, pancreatic ductal adenocarcinoma (PDAC) tumors



(legend on next page)

are characterized by a dense stroma consisting of cancer associated fibroblasts (CAFs) that have a dual role in promoting and hindering tumor growth. We sought to adapt the rules framework to model CAF and tumor cell interactions informed by ST and single-cell RNA sequencing (scRNA-seq) datasets of PDAC. Our previous studies of cell-cell interactions in scRNA-seq analysis and organoid co-cultures found that fibroblasts induce epithelial-to-mesenchymal transition (EMT) in neoplastic cells through communication via the extracellular matrix (ECM)-sensing integrin receptor ITGB1.⁶⁷ This neoplastic cell phenotype was mutually exclusive with proliferative signaling in epithelial cells. Therefore, we encoded two neoplastic cell subtypes in our model: an epithelial cell type that proliferates and a mesenchymal cell type that undergoes EMT but does not proliferate (Figure 3A).

The tumor cell states and parameters in our oxygen-dependent tumor growth model provided a foundation for modeling the neoplastic cell states in PDAC, particularly the proliferative phenotype associated with the more epithelial-like neoplastic cells. The more complex biophysical impact of fibroblast and ECM interactions and the precise cellular behavior of EMT in this mesenchymal subtype of cells were not sufficiently well described to encode model rules or parameters. To address this limitation, we performed single-cell tracking experiments⁶⁸ to assess the impact of both the ECM and fibroblasts on human pancreatic tumor cells. Co-culturing PDAC cells with CAFs increased motility except in the highest ECM concentrations, as compared with monoculture, leading us to hypothesize that increased cell motility is a dominant feature of fibroblast-mediated signaling on neoplastic cells (Figures 3B, S5, S6, S7, and S8; Methods S1). These data also showed that ECM density has a complex effect on neoplastic cell motility: as collagen-I density was increased in monoculture, tumor cell motility first increased and then decreased, which was consistent with prior published observations from other cancer types.^{68,69}

Based on our gene expression analysis and these experimental data, we hypothesized that fibroblasts secrete factors that both alter ECM density and promote neoplastic cell phenotype changes to increase motility in the co-culture condition. We encoded these 2-fold effects in the ABM (where signaling from fibroblasts promotes EMT in neoplastic cells) by adding secretion of a simulated factor from fibroblasts, which promotes a phenotypic shift from epithelial-like to mesenchymal-like. This transformation rate depended on the local ECM density, with the rate increasing from 0 to 0.01 min⁻¹ as the ECM density increases. We described the neoplastic cell motility response to its local ECM density using two Hill functions, which combined


to produce the biphasic motility behavior observed in our experiments (Figure S9; Methods S1). Based on the notable sensitivity of our ABM to motile neoplastic cells, we sought to further use our experimental data to parameterize motility rates in this ABM to more accurately reflect PDAC biology. To isolate the CAF signaling effect on mesenchymal-like neoplastic cell motility from the effect on EMT induction, we used the *in vitro* PDAC monoculture cell motility data to parameterize the *in silico* migration rate of mesenchymal cells as a function of ECM density (Figures S3 and S9; Methods S1). In this way, the fibroblasts in this model could shift the microenvironment in favor of tumor progression, consistent with the hypothesis generated from our transcriptional signatures and the *in vitro* cell motility data. Finally, to encode the switch between this mesenchymal phenotype and the alternative epithelial-like subtype, we simulated a simple (generalized) pro-inflammatory factor which was pro-tumorigenic and induced proliferative signaling in the epithelial-type neoplastic cells.

To first simulate the impact of CAF density on cancer progression, we generated a series of ABMs of virtual co-culture experiments at varying cell densities. We initialized the model by seeding a total of 1,000 cells at various PANC:CAF ratios (using the rules and parameters derived above to simulate Panc 10.05 and HT-231 cell behavior) for 7 simulated days (Figure 3C; Videos S1–S8). In the simulations, fibroblasts promoted tumor cell invasion. We sought to quantify the impact of fibroblast density on this invasion by counting the number of invasive projections of simulated tumor cells away from the central tumor mass over time (STAR Methods). By 24 h, the simulated co-cultures all had a significant increase in invasion relative to simulated monoculture, with the highest levels of invasion observed in the 10:1 and 5:1 PANC:CAF ratio simulations (Figure 3D). This enhanced invasion in the 10:1 and 5:1 PANC:CAF ratio simulations was observed across all time points, while the 2:1 PANC:CAF simulation reached a similar level of invasion at later time points. On the other hand, the 1:5 and 1:10 PANC:CAF ratio simulations reach similar levels of invasion to monoculture at later time points.

To validate the observed impact of CAF-related signaling on neoplastic cell invasion, we also performed *in vitro* cultures of a panel of patient-derived PDAC organoids in CAF-conditioned media and measured the change in invasion (Figure 3E). While PDAC organoids invaded when embedded in collagen alone,⁷⁰ we observed significantly increased invasion in the CAF-conditioned media in these experiments, consistent with the hypothesis that secreted factors from CAFs are sufficient to induce invasion. One limitation of our model was its abstraction into a single

Figure 3. CAFs support the epithelial-to-mesenchymal transition in simulated pancreatic epithelial cells, which promotes invasive growth and the establishment of new epithelial-like foci

- (A) Schematic of the CAF-epithelial model.
- (B) Monoculture and co-culture PANC migration speed vs. ECM density.
- (C) Simulation of CAF-epithelial dynamics initialized at a CAF:epithelial ratio of 1:1 over 7 days.
- (D) Mean invasiveness for each simulated admixture (PDAC:CAF).
- (E) Patient-derived pancreatic organoids (PDOs) are significantly more invasive when cultured in inflammatory CAF (iCAF)-conditioned media as compared with control.
- (F) Schematic of the extended CAF-epithelial model for integration with Visium data.
- (G) Simulations of samples PDAC01 (bottom row) and PDAC02 (top row) Visium tissue over 15 days. (Bar: 200 μ m.)



(legend on next page)

CAF subtype. To test whether this was sufficient to capture the invasive process, the invasion assays in PDAC organoids were performed in conditioned media from inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs).⁷¹ We observed similar levels of invasion with both CAF subtypes, supporting the abstraction of a single subtype of CAFs for our initial models (Figure S10).

We next sought to identify the potential of adapting our ABM to forecast cellular states based on initial conditions from human tissue. For this mathematical model, we initialized cell positions in a virtual tissue based on Visium ST data from two human PDAC lesions selected for their high fibroblast density⁷² (Figures 3F and 3G). Our bioinformatics methods for three-way integration between H&E imaging data, ST, and transcriptional signatures of cellular phenotypes⁷² (see STAR Methods) were used to categorize and position the epithelial-like and mesenchymal-like neoplastic cell phenotypes, fibroblasts, and ECM in our model. Other cell types identified in the Visium data were modeled as essentially inert, providing structure and scaffolding for the tumor cells and CAFs. Cellular phenotypes annotated in the two Visium datasets were input into PhysiCell and used to initialize two distinct ABMs. Each lesion's development was forecasted for 15 days (Figure 3G; Videos S9 and S10). We observed a transitory state in which the neoplastic cells transitioned from mixed epithelial and mesenchymal states to become nearly uniformly mesenchymal due to interactions with fibroblasts. Subsequently, groups of epithelial neoplastic cells arose in both models and even invaded beyond the tumor boundary.

Initializing the ABM from ST data could also estimate regional changes to cellular phenotypes and the impact of tumor heterogeneity. In both simulations, an interface of mesenchymal neoplastic cells was maintained between the epithelial neoplastic cell and fibroblast cell masses. In PDAC02, rapidly dividing epithelial neoplastic cell clusters arose from lesions not surrounded by fibroblasts and invaded the bounding pancreatic cells. In contrast, the dense, uniform fibroblasts surrounding all of the lesions in PDAC01 slowed invasion. The reduced rate of invasion resulted in smaller invasive lesions at 15 days in the PDAC01 sample compared with PDAC02. Whereas all the lesions in PDAC02 invaded the bounding pancreatic cells, PDAC01 developed an epithelial neoplastic cell mass constrained from further motility by the surrounding CAFs and dense ECM they had constructed. These computational predictions showed the hypothesized neoplastic-fibroblast interactions inducing the transition between classical (epithelial-like) and basal (mesenchymal-like) pancreatic transcriptional subtypes,

as observed in primary human pancreatic tumor progression, and the return to a more epithelial-like classical subtype at metastatic sites.^{73–75} Moreover, the spatially resolved simulations from tissue also demonstrated how CAFs, despite their tumor-promoting behavior, can also serve as a physical barrier to prevent neoplastic cell invasion. These simulations of PDAC showed how we can parameterize ABMs from transcriptional analysis and cellular-level biophysical measurements, yielding simulations that inform experimentally testable hypotheses.


Development of immune resistance in a diverse TME of T cells and macrophages

To introduce virtual immune cells, we extended the ABM by including CD8⁺ T cell agents capable of contact-mediated cytotoxic killing, as well as phenotypically diverse macrophage populations. We developed the rules so that CD8⁺ T cells were also stimulated by pro- and anti-inflammatory factors that modulate the probability that killing will occur after a given cell contact. Simulated macrophages switched between promoting and suppressing tumor killing (secreting a pro- or anti-inflammatory factor, respectively) depending on the oxygenation in their immediate surroundings and as described in the literature.^{76–78} Macrophages were also responsible for phagocytosing dead cells and could increase secretion of pro-inflammatory factors, attracting CD8⁺ T cells that homed to the tumor by following this chemokine. CD8⁺ T cells could attack and damage malignant epithelial cells, and accumulated damage could cause tumor cell death. In tissue culture, macrophages can be polarized into cell states commonly referred to as M1 and M2. These phenotypes are plastic, and in our ABM, macrophages could transition between M1-like and M2-like depending on the signals in its environment, consistent with the literature^{76–78} (Figure 4A).

We used these rules to simulate 5 days of growth of a 2D tumor in tissue culture in a virtual environment of 38 mmHg oxygenation (physiologic conditions⁶⁵), starting with 2,000 viable tumor cells seeded randomly, surrounded by a ring of immune cells seeded with 100 of each non-tumor cell type (Figure 4B). Through these simulations, we observed that CD8⁺ T cells clustered together and migrated throughout the tumor along with macrophages to accomplish tumor clearance, with a corresponding dominance of pro-inflammatory factor as the simulation proceeded (Figures 4C and 4D). This model showed how the innate and adaptive immune systems cooperated in the task of tumor sensing and clearance and demonstrated a simplified, plastic M1-like to M2-like axis of macrophage behavior in tissue culture, marked by rapid and reversible changes along this axis. We anticipated that the parameterization of immune cell models

Figure 4. A simulated tumor evades cytotoxic killing by manipulating its immune microenvironment

- (A) Schematic of the tumor-immune interaction model.
- (B) Simulation of tumor-immune interaction model over 5 days showing tumor killing.
- (C) Time series of average substrate levels surrounding CD8⁺ T cells. Shaded regions indicate one standard deviation.
- (D) Time series of tumor cell count. Shaded regions indicate one standard deviation.
- (E) Schematic of the extended tumor-immune model, with three possible macrophage states and three CD8⁺ T cell states.
- (F) Simulation of extended tumor-immune model over 5 days, showing tumor survival after exhausting T cells and pushing more macrophages to the M2-like state.
- (G) Time series of average substrate levels surrounding CD8⁺ T cells. Shaded regions indicate one standard deviation.
- (H) Growth curves for all populations; the right plot zooms in to show just the immune dynamics, the exhaustion of T cells, and the switch toward M2-like macrophages. Shaded regions indicate one standard deviation.



(legend on next page)

would also impact simulations results. By default, we chose parameter values based on existing literature^{79–82} to ensure biological relevance. To further investigate parameter sensitivity, we applied our new parameter sensitivity toolbox enabled by our rules to perform a local sensitivity analysis around the selected parameters using multiplicative perturbations of 1%, 5%, 10%, and 20%. We observed that while these perturbations introduced variation in the Qols, they preserved the central tendency of the model outputs. We found that the half-max oxygen value for macrophage polarization had the greatest impact on the selected Qols (Figures S11 and S12). This uncertainty quantification was consistent with the significant impact of macrophages on immune response and immunosuppressive progression during carcinogenesis.

To further model immune response initiation and macrophage-mediated resistance in tissue culture, we extended the immune cell subtypes in our model to represent M0-like, M1-like, and M2-like macrophages and naive, activated, and exhausted CD8⁺ T cell subtypes (Figure 4E). While *in vivo* macrophage populations do not polarize into discrete states in this way, we applied these categories as ways of broadly characterizing macrophages as either pro- or anti-inflammatory. Interleukin-10 (IL-10) and interferon (IFN)- γ modulated the activation of naive T cells with (pro-inflammatory) IFN- γ promoting and (anti-inflammatory) IL-10 inhibiting this activation. In the activated CD8⁺ T cell compartment, IFN- γ and IL-10 promoted proliferation and exhaustion, respectively. We initialized the tumor as before with 2,000 tumor cells inside a disc. The immune compartment was initialized with 400 M0-like macrophages and 400 naive CD8⁺ T cells in a ring around the disc of tumor cells (Figure 4F). ABM simulations demonstrated dynamics where pro- and anti-inflammatory factors occupied the neighborhood of the CD8⁺ T cells in roughly equal proportions throughout the simulation (Figure 4G) that initially caused the tumor population to shrink by more than 50% before recovering to nearly its original volume by day 5 (Figure 4H). This was facilitated by an immune compartment that initially had a rapid activation of naive T cells and a slower exhaustion of these newly activated CD8⁺ T cells (Figure 4H). The macrophage compartment accelerated both shifts with M1-like macrophages secreting IFN- γ to help activate T cells and later M2-like macrophages secreting IL-10 to induce CD8⁺ T cell exhaustion. The level of hypoxia modulated the balance between the M1-like and M2-like macrophage populations through its regulation of the transition from the pro-inflammatory M1-like state to the anti-inflammatory M2-like state.

By the end of the simulation, the CD8⁺ T cell compartment was entirely exhausted, and the macrophage compartment inside the tumor boundaries was entirely M2-like (Figures 4F, later time points and 4H), permitting significant tumor regrowth. These immune dynamics were responsible for the initial CD8⁺ T cell-induced regression of the tumor and subsequent resistance to immune attack, as commonly observed in late-stage, immunosuppressive tumors.


Modeling macrophage-induced invasion generates the experimentally testable hypothesis that EGFR signaling promotes neoplastic cell motility in breast cancer

Because CD4⁺ helper T cells are a major component of the tumor immune ecosystem that modulates the immune response on tumor progression,⁸³ we sought to extend our ABM investigation to uncover mechanisms associated with immune-induced tumor progression by simulating the influence of CD4⁺ helper T cells on epithelial cell behaviors. Notably, DeNardo et al. previously demonstrated that signaling from Th2 CD4⁺ T cells to macrophages can induce pro-tumorigenic effects in the MMTV-PyMT murine breast cancer spheroid model.⁸⁴ Briefly, the study demonstrated that Th2 CD4⁺ T cell signaling promotes changes in macrophage phenotype, making them more likely to produce EGF and therefore stimulate EGFR signaling in tumor cells driven by immunosuppressive macrophages, promoting invasive behavior via EGFR signaling (Figure 5A). We sought to determine if our ABM simulations can reproduce this emergent, seemingly counter-intuitive tumor-promoting behavior arising during immune response.

We first sought to simulate the series of experiments from DeNardo et al.⁸⁴ that used a tumor spheroid co-culture model to evaluate the impact of macrophage phenotypes on invasion. Briefly, we simulated the M1-like macrophages as pro-inflammatory and M2-like macrophages as anti-inflammatory, and we encoded their role in phagocytosing dead cells and secreting pro- and anti-inflammatory factors. In this system, the M2-like macrophages also promoted pro-tumorigenic signaling in the neoplastic cells through the EGF-EGFR signaling pathway (Figure 5B). We used these rules to simulate 5 days of virtual spheroid growth in 38 mmHg oxygenation (physioxia⁶⁵), starting from 200 viable tumor cells seeded randomly, surrounded by macrophages overlaid in co-culture where 10 of each immune cell type (macrophage, T cell) are seeded. As a first step in mirroring the macrophage promotion of tumor invasion, we simulated EGF secretion from M2-like macrophages activating

Figure 5. Tumor-associated macrophages in M2-like polarization state assist simulated invasive breast cancer spheroids through EGF signaling

- (A) Example fluorescence microscopy image showing macrophages (red) proximal to an invading PyMT organoid (green), with DAPI shown in blue indicating cell nuclei, as an additional replicate image of the experiments described originally in DeNardo et al.⁸⁴ (Bar: 20 μ m.)
- (B) Schematic of the tumor-associated macrophage (TAM)-EGF model, including TAMs, CD4⁺ T cells, and neoplastic epithelial cells.
- (C–E) Endpoint snapshots of simulations in which EGF signaling causes neoplastic cells to increase proliferation (C), increase motility (D), and increase both proliferation and motility (E).
- (F) EGFR inhibitor inhibits MMTV-PyMT invasion into 3D collagen I in a dose-dependent manner. **** $p < 0.0001$ (Kruskal-Wallis followed by Dunn's multiple comparisons test).
- (G) Stimulated MFC10a breast epithelial cells exhibit increased motility when exposed to EGF, with increasing median migration speed as more cells escape the tumor bulk for unrestricted migration.
- (H) Endpoint snapshots treated with IFN- γ (left panel) and IL-4 (right panel).
- (I) Endpoint snapshot with Th2-like CD4⁺ T cells.



(legend on next page)

pro-tumorigenic behavior of neoplastic cells through EGFR. Canonically, EGFR signaling is hypothesized to act primarily by promoting tumor progression by inducing neoplastic epithelial cell proliferation, which we term the “grow hypothesis.” We simulated this by specifying a Hill response rule with the signal of EGF modulating cell-cycle entry in malignant epithelial cells, using the hypothesis grammar (Figure 5C; Video S11). However, these simulations did not demonstrate the macrophage-induced invasive tumor structures from DeNardo et al.⁸⁴ Our PDAC simulations demonstrated that enhanced cellular motility was critical to simulate invasion. We modeled EGFR signaling from macrophages as promoting motility in breast cancer cells, a hypothesis supported experimentally.^{85,86} We term this the “go hypothesis” (Figure 5D; Video S12). We simulated this increase in motility using a grammar rule specifying a Hill response function between EGF and malignant epithelial cell motility. The experimentally observed invasive phenotype was recapitulated in models in which EGF induced only changes to motility (Figure 5D) and models where EGF induced both motility and proliferation (Figure 5E; Video S13).

Our simulations led to the hypothesis that EGF-EGFR signaling in breast cancer cells promotes invasive outcomes primarily through modulating malignant epithelial cellular motility. To test these computational predictions experimentally, we treated organoids derived from the same MMTV-PyMT model with the EGFR inhibitor gefitinib. These experiments demonstrated that inhibition of EGF receptor signaling reduced the ability of neoplastic cells to form invasive protrusions (Figure 5F) and only reduced colony formation at extremely high doses of gefitinib treatment (Figure S13). In addition, MCF10A mammary epithelial cells exposed to EGF showed both increased proliferation and increased motility (Figures 5G and S14). Together, these experiments confirmed our computationally driven hypothesis that macrophage-induced invasion arises from EGFR signaling promoting neoplastic cell motility, consistent with the go hypothesis or go and grow hypotheses.

We next sought to integrate the effect of Th2-like CD4 helper T cells that secrete cytokines, which we⁸⁴ and others⁸⁷ have shown skew macrophages toward M2-like phenotypes and induce their proliferation. Mirroring the DeNardo et al. experiments, we performed *in silico* stimulation of the MMTV-PyMT-macrophage co-culture system first with the cytokine IFN- γ and then with IL-4. In our simulations, we observed that IFN- γ completely constrained tumor growth, whereas IL-4 promoted macrophage polarization toward an M2-like phenotype, inducing their proliferation and secretion of EGF into the local environment. The increased EGF levels then promoted tumor

proliferation and motility, resulting in an expansion of tumor volume, compared with the IFN- γ condition (Figure 5H). Finally, we layered Th2-like CD4⁺ T cell agents into our model, which acted as cellular sources of IL-4 and promoted invasion similarly to the simulated high IL-4 dose, but with a more irregular shape resulting from a more irregular supply of IL-4 and subsequently EGF around the tumor boundary (Figure 5I). Taken together, these results support a dual role for EGF in promoting invasion. They also demonstrated how the rules-based modeling framework allows for *in silico* testing of cellular hypotheses of experimental phenomena and how it supports distinguishing alternative mechanistic hypotheses that can subsequently be tested experimentally to build toward a systems-level model of emergent, unanticipated cell behavior.

Leveraging the hypothesis grammar for virtual clinical trials: Using human scRNA-seq data from PDAC to simulate immunotherapy combinations

Encoding the tumor microenvironment (TME) in our ABM can simulate the impact of immune cell composition and perturbations on tumor growth. We sought to adapt this framework to simulate the impact of different immune-targeted therapies in the PDAC microenvironment to develop a virtual simulation of a clinical trial. In particular, we were motivated by a recent neo-adjuvant clinical trial^{88,89} that sought to enhance T cell-mediated cytotoxicity in PDAC by adding Urulemab (an anti-CD137 agonist therapy) to a combination of GVAX (an irradiated, granulocyte-macrophage colony-stimulating factor [GM-CSF]-secreting, allogeneic PDAC vaccine)⁹⁰ and Nivolumab (an anti-PD-1 immune checkpoint inhibitor). To generate the model rules reflecting this clinical trial, we used observations from high-throughput transcriptomic data (Figure 6A), our preceding immune cell models, and additional literature-derived hypotheses about the phenotypes of immune cells (Figure 6B). Owing to the nature of these therapies, we implemented rules to model T cell, tumor cell, and macrophage behavior. We used template rules for tumor cells and macrophages, modeling proliferative tumor cells as in previous ABM examples and macrophages as plastic between pro- and anti-inflammatory states but biased toward anti-inflammatory factor secretion. We then developed rules for T cells. To reflect the therapeutics in the trial design, we modeled CD4⁺ and CD8⁺ T cells subtyped based on their PD-1 and CD137 expression. Multi-omics data from the arms of this trial, comparing GVAX monotherapy with the combination with Nivolumab, demonstrated that PD-1 inhibition activates chemokine signaling in CD4⁺ T cells, thereby signaling to CD8⁺ T cells to promote changes in lymphocyte chemotaxis.⁹¹ Based

Figure 6. Combination immunotherapies simulated for a cohort of untreated pancreatic adenocarcinomas based on immune cell proportions estimated from scRNA-seq data

- Expression of marker genes of interest within immune populations in immune-enriched scRNA-seq data in a cohort of PDAC tumors from Steele et al.⁹²
- Schematic of the combination immunotherapy model.
- Populations of interest identified for each tumor profiled in the reference scRNA-seq data.
- Tumor growth curves per each tissue initial conditions without therapy, with images shown at the simulation endpoint for select samples.
- Growth curves under each therapy condition for three example tissues, with endpoints shown.
- Tumor growth curves for the triple-therapy treatment condition (ICI + URU + GVAX), images shown at simulation endpoint for select samples.
- Macrophage and CD8 T cell population relative abundances in tissues, binned by whether the simulation with GVAX + ICI + URU reached the tumor clearance threshold (final/initial $\times$ 100% < 50%). Macrophage abundance was significantly higher in tissues whose simulations reached the tumor clearance threshold (p = 0.005606), while CD8⁺ T cell abundance did not show a significant difference (p = 0.5509).

on these data, we created distinct model rules for T cells based on their PD-1 expression, specifically that CD4⁺ T cells secrete chemokines that attract CD8⁺ T cells (here designated pro-inflammatory factor). We performed further ligand-receptor analysis of cell-cell signaling associated with CD137^{hi} CD8⁺ T cells using scRNA-seq data from untreated PDAC tumors and found that CD137^{hi} CD8⁺ T cells have higher signaling through IFN expression than their CD137^{lo} counterparts.⁹¹ We modeled this subtype-specific IFN expression by specifying that CD137⁺ cell agents secrete an inflammatory factor substrate into the surrounding environment. Stimulation through the CD137 transmembrane receptor is also known to make CD8⁺ T cells more effective at killing, which we simulated by modeling CD137^{hi} CD8⁺ T cells as having a higher killing rate than their CD137^{lo} counterparts and having the ability to kill tumor cells independent of their PD-L1 status.

We then simulated the effect of therapy on different microenvironments—a key step to creating virtual clinical trials that explore therapeutic response across a variety of tissue conditions. Using the rules to generate virtual clinical trials requires having both a mechanism of action of the therapies in our rules and the immune cell compositions for a cohort of virtual PDAC tumors. We simulated the effect of therapy by modifying the proportion of each T cell subtype consistent with the canonical mechanism of action of that therapy. Specifically, we simulated GVAX treatment by a doubling of all T cell populations in the TME, Nivolumab therapy by turning PD-1^{hi} agents into their PD-1^{lo} counterparts and PD-L1^{hi} agents into PD-1^{lo}, and Urelumab by turning all CD137^{lo} agents into CD137^{hi} agents. We kept these cellular interaction rules consistent across all individual simulated patients; the efficacy of a simulated treatment thus depended upon the proportion of immune cell populations in each virtual patient. To simulate clinically relevant immune compartments, we generated an *in silico* cohort of tumors based on the immune cell-type distributions in untreated scRNA-seq data from Steele et al.⁹² To mirror the cellular phenotypes in our model rules, we re-annotated the scRNA-seq data from Steele et al.⁹² as described by Guinn et al.⁶⁷ and Li et al.,⁹¹ sorting T cells into hi/lo categories based on *TNFRSF9* (CD137) and *PDCD1* (PD-1) gene expression⁹¹ (Figure 6C). Tumor cells were classified as PD-L1^{hi} and PD-L1^{lo}, based on scRNA-seq measurements of *CD274* (PD-L1). In our simulations, we initialized each microenvironment with 1,000 tumor cells, with the proportion of PD-L1^{lo} to PD-L1^{hi} expression from the scRNA-seq data.

We then combined our cell rules and TME composition from the scRNA-seq cohort to demonstrate how our modeling framework can be applied to test hypotheses about the impact of the TME composition on response to different therapies. As a virtual control to test the impact of therapeutics, we also ran these simulations for the baseline TMEs without therapy. The simulations from most patient microenvironments predicted neoplastic cell population growth without treatment after 7 simulated days. We then applied the simulations for each candidate therapy alone or in combination to each microenvironment; these simulations demonstrated inter-patient heterogeneity of treatment effects (Figures 6D–6F, S15 and S16). The baseline tumor growth profiles vary from near elimination (tissue 8) to uncontrolled tumor growth (tissue 11A), with others falling in between

(Figure 6D). At endpoint, several simulated tissues displayed local aggregations of T cells, which were enriched in our simulated treatments, similar to the lymphoid aggregates found after immunotherapy treatment in biospecimens from human clinical trials^{88,93} (Figures 6D–6F, S17 and S18).

An advantage of our modeling framework is that it can simulate the temporal dynamics of cellular phenotypes observed in the TME. These temporal simulations provide the opportunity to evaluate the impact of the TME composition on simulated reduction in tumor volume (Figures S19–S26). In our simulations, we observed a statistically significant higher abundance of macrophages between responders and non-responders to triple combination (Figure 6G). While the triple combination converted the most T cells to the best killing state, we found that single or double combinations outperformed the triple combination for several tissue ABMs in the cohort. These simulations led to a new biological hypothesis that macrophage clearing of tumor cells is essential for lymphocyte trafficking and tumor cell killing in PDAC. We note that this hypothesis generated from our mathematical simulations is consistent with clinical observations of increased TREM2⁺ macrophage signaling to tumor cells in the triple combination.⁸⁹

Encoding asymmetric cell division in rules enables extension of the hypothesis grammar beyond cancer to simulate formulation of layers in brain development

To demonstrate the generalizability of our hypothesis grammar coded in PhysiCell across biological systems, we sought to apply it to simulate layer formation during cortical development in the brain. The laminar organization of different cell types is an archetypal property of vertebrate neural systems. This cytoarchitecture not only replicates across species but across multiple tissues (e.g., retina, hippocampus, cortex) within the central nervous system. Modeling this formation is particularly significant, as disruption and disorganization of the layers is found in both neurodevelopmental and neurodegenerative diseases.⁹⁴ We modeled the formation of this laminar structure by leveraging the rules grammar. While the previous examples in cancer all relied on symmetric cell division, this phenomenon is driven by a combination of symmetric and asymmetric division of progenitors. Specifically, stem cells undergo asymmetric division in which one daughter cell retains its stemness while the other differentiates into a cell fated to a specific layer of the developing brain (Figure 7A). After differentiation, the cells begin migrating toward the pial layer, ending their migration upon contact with the pial layer. The sequence of differentiation into the cortical layers is controlled by the time passed in the neural development using the hypothesis grammar. Additionally, the grammar controls the stem cell division rate, slowing their cycling as time elapses. This in turn increases the overall length of the cell cycle, replicating what is observed *in vivo*. Together with the previously described functionalities, these parameters can generate the cellular diversity and tissue structures prototypical in neural development.

To demonstrate the flexibility of the rules grammar to model neural development, we used the Allen Brain Atlas⁵³ to quantify the laminar structure of two regions in the adult mouse brain and calibrate the rules parameters to match each of these regions in




Figure 7. Region-specific laminarization of the cortex

(A) Schematic of the formation of the cortical layers in the neuro-development model.
 (B) Storyboard of the formation of the somatosensory cortex (SOM) after calibration.
 (C) Extraction of layer counts in the SOM from a single z slice in the Allen Brain Atlas.⁵³
 (D) Layer counts after calibration for both the SOM and auditory complex (AUD). Black dots represent the counts found from the atlas.
 (E) Extraction of the layer counts in the AUD from a single z slice in the Allen Brain Atlas.⁵³
 (F) Storyboard of the formation of the AUD after calibration.

turn. We chose the somatosensory cortex (SOM) and the auditory cortex (AUD). Specifically, we used single z slices of the atlas, extracting all cells in that slice from the given region. To quantify the relative abundance of cells within each layer of a given region, we further subset to a rectilinear subspace of the section. Whereas our previous models used spatial data to initialize the model states, here, we fit model parameters to minimize the residual sum of squares of the thickness of the layers at the final time point of the simulation. By fitting the rule parameters to datasets representative of the endpoint of the simulation when the brain regions have fully formed, we are able to successfully produce the laminar structure of both the SOM (representative simulation in Figure 7B, extracted brain atlas data in Figure 7C, and calibrated cell counts in Figure 7D, left) and the AUD (brain atlas data in Figure 7E, with calibrated cell counts in Figure 7D, right) in our ABM. These simulations demonstrate that we can use static, spatial multi-omics data to extend beyond model initialization to more complex model calibration for parameter fitting shown here.

DISCUSSION

The real-world limitations of characterizing the dynamics of cellular and molecular changes in human-focused research, especially for snapshots of spatial multi-omics, do not exist *in silico*. Computational models can guide and supplement lab experiments. For example, the NCI digital twins initiative aims to develop models of patient tumors to predict which therapies will most benefit each individual,^{29,31} by simulating many replicates of their system's behavior over time and under different sets of conditions. The ability to perform large numbers of replicates and numerous iterations cheaply and easily maximizes the chance of capturing extremely rare critical events. ABMs abstract biological systems to run *in silico* experiments thousands or millions of times, whose parameters and in-built hypotheses are all readily modifiable by the user. The new conceptual framing (a grammar) for specifying cell behavior hypotheses introduced in this study can systemize and facilitate our thinking of how cells interact to drive tissue ecosystems. The grammar made it possible to introduce new capabilities in the PhysiCell

ABM framework, thus simplifying the workflow to generate ABMs of multicellular systems.

Previously, custom hand-written code and a high level of technical knowledge were required to implement even basic models. Our hypothesis grammar can encode complex cellular behaviors and responses to signals in single lines of human-readable text. When used in combination with graphical and cloud-based modeling frameworks,^{56,95} the barrier to entry into using ABMs is considerably reduced. In this implementation, it is simple to modulate and apply behaviors to different agents in the system in plain text without requiring writing code or editing machine-readable markup languages. Further, PhysiCell is open-source, community-built ABM software that encodes a vast amount of biological and computational knowledge at baseline; however, everything is completely customizable, extensible, and modifiable. Moreover, this cell behavior grammar affords an opportunity to systematically collect, annotate, curate, and grow our knowledge of cellular behaviors and interactions for use as model templates.^{51,96}

We demonstrated a variety of models extending from carcinogenesis and immune response to tumor growth and demonstrating broader extensions to neurodevelopment. Some of these models have all cellular agents following the same rules and fate determined by the actions of those around them. In other models, cell agents act at cross purposes and actively seek to outcompete, evade, or hunt and kill each other. We modeled immune processes such as macrophage plasticity, T cell activation and expansion, antigen recognition, and inflammation. The rules for these examples are all available to be re-run on any user machine, providing sample case studies for new users. These case studies also showcased how ABMs can be applied for *in silico* experimentation of complex multicellular processes, which can prioritize new hypotheses for experimental validation or exploration.

The models in this study also directly translated cellular location and identity from ST data to initialize an ABM. Thus, models can now directly match the tissue structure and transcriptional profile of samples. Spatial relationships between cells and cellular neighborhoods significantly impact outcomes. This strong dependence of many cancer systems and ABM trajectories on initial conditions can complicate model inquiry and impact critical system behaviors and model parameters obtained through inference; by leveraging robust single-cell ST tissue profiles as initial conditions in the digital modeling stage, the hypothesis-driven rules modeling paradigm is grounded in precise referential data but also offers a path to both stronger model inquiry and more confident mathematical inference. These models nonetheless still require annotation of a finite number of agents identified in spatial molecular data, often annotating cells into broad phenotypes and abstracting cellular subtypes. Future work must evaluate the sensitivity of models to the granularity of cellular phenotypes in these high-throughput datasets, accurate inference of parameters in the resulting higher-dimensional models, and curation of best parameter estimates for community reuse of omics-informed ABMs.

The cell-based nature of our mathematical framework can predict the impact of distinct immunotherapeutic combinations on altering the TME. We also showed that these model predictions can be further personalized by inputting baseline cellular

abundance measurements, providing a powerful tool for selecting optimal combinations to overcome the immunosuppressive landscape of many solid tumors. Limitations of testing combination therapies experimentally are the large number of experiments required to test ordering, therapies with distinct mechanisms of action, and biological variability of TMEs. The ability of ABMs to simulate systems-level cellular behaviors entirely *in silico* provides an effective means to pre-screen combinations at scale to prioritize therapeutic selection and order of delivery in preclinical and clinical studies. Metrics to benchmark mathematical models both qualitatively and quantitatively against real-world preclinical and clinical studies are essential to fully leverage these models to predict personalized biological conditions. This grammar must also be extended to simulate the pharmacokinetics and pharmacodynamics encoded in more complex quantitative system pharmacology models to fully empower virtual clinical trials.⁹⁷ While our models demonstrated the potential of our software to simulate virtual clinical trials, translating these models to the clinic requires robust calibration and validation of their ability to fully mimic the behavior of human clinical trials. Moreover, the focus of our model on simulating cellular perturbations in local tissue environments limits our predictions to estimating local cellular landscape only, requiring complementary preclinical or clinical studies. We view our framework as ideally suited to prioritize candidate targets for these combinations, still requiring extensive clinical and regulatory evaluation prior to usage as precision medicine tools beyond the scope of this study.

This language framework will be useful to those seeking to build models of multicellular systems, and we are excited to continue to move toward fuller biological completeness and more complete integration with omics data, to increasingly define agent behavior in an automated and a data-driven fashion. These advancements expand the functionality, usability, and compatibility of our approach, empowering interdisciplinary researchers in their computational or systems biology endeavors. These advancements expand the functionality, usability, and compatibility of our approach, empowering researchers across disciplines to unlock the full potential of their single-cell data. Armed with this conceptual framing and tools, they can extrapolate beyond single-cell characterizations for multicellular systems biology and ultimately perform virtual cellular and tissue experiments.

Limitations of the study

In any computational framework, all required biology must be built from the ground up. The hypothesis grammar for PhysiCell enables many cellular behaviors, but many important aspects remain to be added. In future work, we plan to further refine the hypothesis grammar to expand its usability and flexibility. We are considering incorporating keywords for “wild card” rules (e.g., in all cells, mechanical pressure decreases cycle entry) and other special cases using regular expression-type syntax, as well as extensions (e.g., “low S” or “decreasing S”) that can simplify the examples presented in this paper. Moreover, we plan to add extensions for hysteresis and delayed activation in our responses and for allowing cells to access the properties of contacting cells as signals or inputs to rules (e.g., for delta-Notch signaling or improved antigen recognition). While our software

can use multi-omic and spatial molecular data for model initialization and some parameterization, the ability to encode rules directly from inferred regulatory networks and to incorporate uncertainty analyses in the input of these data remains an important area of ongoing research. Moreover, emerging large language models (LLMs) such as ChatGPT may facilitate “translation” of familiar language (e.g., fibrosis) into the smaller set of symbols in the current grammar. The language currently treats all statements as independent (inclusive OR), but we may need additional language operators to signify relationships between rules such as AND or REQUIRES. Other generalizations and improvements to the forms of response curves, consensus process models, and default parameter values are likely to emerge from widespread community use, feedback, and discussion.

Our current grammar is focused on cellular interactions, but it does not yet incorporate gene regulatory networks, although intracellular gene regulatory networks are supported in PhysiCell.^{98,99} While we demonstrated initialization and parameterization from ST data, our software requires further extensions to fully interoperate with omics data analysis ecosystems and emerging high-throughput data modalities. In the models presented here, the connections with the data rely on macroscale summaries of the data such as size of the tumor, cell-type annotations, or thickness of cortical layers. Increasing the depth of connection to the data—spatially, temporally, and phenotypically—will improve the accuracy and predictive power of these models.^{100,101} Further parameter fitting and data assimilation methods are also needed to fully embed experimental data into the models to ensure biologically calibrated ABMs. For example, we note that well-known developmental timings were used to drive the evolution of fate specification in the corticodevelopment example^{102,103} to allow us to focus on key transitions responsible for final cytoarchitecture; future work can integrate Boolean networks⁹⁹ or systems of ODEs to replace time as a proxy signal. A key component of this endeavor is to uncover the roles of all cells in the complex interaction network within any given system and the effect of therapeutic perturbations thereon. In this study, the various models include only a subset of the cell types known to exist in the modeled microenvironments and apply simplified frameworks of pharmacodynamic response. A limitation of our approach is that it relies on cataloging individual cell types and their behaviors,^{51,96} although future work can leverage artificial intelligence to extend beyond manual cataloging by automating discovery with expert quality control. Additionally, future work will establish a community-informed repository to collect and curate biological hypothesis statements grouped as digital cell lines,^{51,96} enabling users to contribute and share cell behavior statements for future reuse in other models of the same system. Continued community input will expand and refine digital cell templates and phenotypic behaviors to actualize virtual cell laboratories.

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Paul Macklin (macklinp@iu.edu).

Materials availability

This study did not create any new materials.

Data and code availability

- PhysiCell Version 1.14.1¹⁰⁴ and later includes a full reference implementation of the grammar and grammar-based simulation modeling, and the specific models in the results are available from https://github.com/physicell-models/grammar_samples.
- Raw data from the cell motility experiment in Figure 5G are provided at <https://zenodo.org/records/14106341>. Spatial transcriptomics data of PDAC tumors are available from GEO: GSE254829. scRNA-seq data from PDAC tumors are available from GEO: GSE155698. Allen Brain Atlas datasets used in this publication are available from <https://knowledge.brain-map.org/data/5C0201JSVE04WY6DMVC/summary>. All other datasets are available from the authors upon request. The simulation sensitivity analysis data are available at <https://doi.org/10.5281/zenodo.14590311>.

ACKNOWLEDGMENTS

Thanks to Jennifer Elisseff, Samantha Guinn, Trachette Jackson, and Ashani Weeratana for feedback; David Tuveson, Dennis Plenker, and Hardik Patel for sharing the hT231 cell line; and Matthew Mayer for assistance with the figures. Cellular wiring diagrams illustrating the rules and the graphical abstract were generated with [Biorender.com](https://biorender.com). Funding was provided by P01CA247886 (to E.M.J., N.Z., L.T.K., J.W.Z., and E.J.F.), K08CA248624 (to N.Z.), U24CA284156 (to E.J.F., P.M., H.L.R., D.R.B., R.H., G.L.S.-O., and A.D.), U01CA294548-01 (E.J.F., P.M., D.R.B., L.W., A.K., and L.M.C.), the Lustgarten Foundation “A Translational Convergence Program of Personalized Immunotherapy for Pancreatic Cancer Patients at Johns Hopkins” (E.M.J., N.Z., L.T.K., J.W.Z., E.J.F., and A.D.), a Lustgarten Foundation-AACR Career Development Award for Pancreatic Cancer Research, in honor of Ruth Bader Ginsburg (to A.L.K.), P50CA062924 (E.M.J., E.J.F., L.D.W., and L.T.K.), U01CA253403 (E.J.F., A.D., and E.M.J.), U54CA274371 (E.J.F., A.K., D.W., and L.D.W.), U01CA212007 (E.J.F. and L.T.K.), U54CA268083 (D.W., A.J.E., A.K., L.D.W., P.H., E.M.J., and E.J.F.), R00NS122085 (G.L.S.-O.), U01CA284090 (A.J.E. and G.L.S.-O.), T32GM148383 (J.M.), T32CA153952 (D.R.B.), T32AG058527 (Y.W.D.), T32CA254888 (E.C.), R35GM157099 (J.M.P.), NSF 1720625 (R.H., Y.W., and P.M.), NSF 2303695 (R.H., H.R., M.G., and P.M.), U54CA209988 (L.M.H.), U54HG008100 (L.M.H.), Anna Fuller Fund (L.M.H.), the Kuni Foundation (L.M.H.), the National Foundation for Cancer Research (E.J.F. and L.M.C.), the Jayne Koskinas Ted Giovanis Foundation for Health and Policy (R.H., M.G., I.G., J.M., D.G., H.L.R., P.M., L.M.H., and Y.H.C.), U01CA232137 (R.H., F.K., and P.M.), NSF 1818187 (R.H., A.S., and P.M.), Leidos Biomedical Research contract 75N91019D00024 (R.H., H.L.R., and P.M.), Maryland Cancer Moonshot Research Grant to the Johns Hopkins Medical Institutions (FY24) (A.D. and E.J.F.), a Luddy Faculty Fellowship (H.L.R. and P.M.), R01CA169702 (L.Z.), R01CA197296 (L.Z.), P30CA006973 (L.Z.), P30CA134274 (L.M.C.), Susan G Komen Foundation (L.M.C.), Brenden-Colson Center for Pancreatic Care (L.M.C.), P30 CA069533 (L.M.C.), the Sol Goldman Pancreatic Cancer Research Center (L.D.W.), the Buffone Family Gastrointestinal Cancer Research Fund (L.D.W.), T32GM141938-03 (E.C.), P30 CA054174 (L.Z.), the Breast Cancer Research Foundation (BCRF-24-048; A.J.E.), Break Through Cancer (E.J.F., A.D., L.D.W., A.K., D.W., L.T.K., J.W.Z., E.M.J., and L.Z.), the NIH Blueprint and Brain Initiative D-SPAN F99NS139554 (N.Z.), and the Maryland Cigarette Restitution Fund Research Grant to the Johns Hopkins Medical Institutions (FY24) (A.D.). D.L.Z. was funded by a Provost’s Undergraduate Research Award (PURA) from Johns Hopkins University and the Summer Student Fellowship from the Institute for Data-Intensive Engineering and Science (IDIES) at Johns Hopkins University. This research was supported in part by Lilly Endowment, Inc., through its support for the Indiana University Pervasive Technology Institute. The Jayne Koskinas Ted Giovanis Foundation for Health and Policy is a private foundation committed to critical funding of cancer research. The opinions, findings, conclusions, or recommendations expressed in this material are those of the authors and not necessarily those of the Jayne Koskinas Ted Giovanis Foundation for Health and Policy or its respective directors, officers, or staff.

AUTHOR CONTRIBUTIONS

Conceptualization, G.L.S.-O., L.M.H., E.J.F., and P.M.; data curation, G.L.S.-O., D.R.B., M.L., J.T.M., L.T.K., E.D.T., N.Z., L.Z., and E.J.F.; formal analysis, J.A.I.J., G.L.S.-O., D.R.B., A.D., A.F., A.L., J.T.M., H.L.R., L.T.K., A.L.K., Y.H.C., L.M.H., E.J.F., P.M., D.L.Z., E.C., Y.W.D., T.L.-V., F.S., M.D., and I.C.M.; funding acquisition, G.L.S.-O., D.R.B., D.W., L.Z., E.M.J., Y.H.C., L.M.H., E.J.F., P.M., Z.N., and L.D.W.; investigation, J.A.I.J., G.L.S.-O., M.B., D.R.B., A.D., H.L.R., L.T.K., A.L.K., E.M.J., L.M.H., E.J.F., P.M., D.L.Z., E.C., Y.W.D., T.L.-V., F.S., M.D., L.D.W., J.M.P., Z.N., and A.S.; methodology, J.A.I.J., G.L.S.-O., M.B., R.H., F.K., D.R.B., E.B., A.D., A.F., M.G., I.G., J.M., J.T.M., A.R., H.L.R., J.S., A.S., Y.W., D.M.G., D.W., P.S.W., J.W.Z., Y.H.C., J.W.G., L.M.H., E.J.F., P.M., and E.C.; project administration, D.R.B., E.J.F., and P.M.; resources, R.H., M.L., H.R., D.M.G., L.T.K., A.L.K., E.D.T., D.W., N.Z., L.Z., J.W.Z., E.M.J., Y.H.C., L.M.C., L.M.H., E.J.F., P.M., D.G.D., A.J.E., L.D.W., J.M.P., and I.C.M.; software, J.A.I.J., R.H., F.K., D.R.B., E.B., M.G., J.M., J.T.M., H.L.R., A.S., Y.W., A.L.K., P.-H.W., Y.H.C., E.J.F., P.M., D.L.Z., and E.C.; supervision, G.L.S.-O., D.R.B., H.L.R., L.T.K., D.W., P.H.W., J.W.Z., Y.H.C., L.M.H., E.J.F., P.M., A.J.E., L.D.W., and J.M.P.; validation, G.L.S.-O., D.R.B., J.W.Z., L.M.C., J.W.G., L.M.H., E.J.F., P.M., E.C., Y.W.D., T.L.-V., F.S., M.D., D.G.D., A.J.E., L.D.W., J.M.P., and I.C.M.; visualization, J.A.I.J., G.L.S.-O., D.R.B., J.T.M., H.L.R., L.M.H., E.J.F., P.M., Z.N., and Y.W.D.; writing – original draft, J.A.I.J., G.L.S.-O., R.H., F.K., D.R., E.B., J.M., J.T.M., H.L.R., A.S., Y.W., Y.H.C., L.M.C., J.W.G., L.M.H., E.J.F., and P.M.; writing – reviewing & editing, all authors.

DECLARATION OF INTERESTS

J.W.Z. receives other support from Roche/Genentech and honoraria from Sermo and ZoomRx. L.Z. receives grant support from Bristol-Myers Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyne. L.Z. is a paid consultant/advisory board member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Tempus, Pfizer, Novagenesis, Snow Lake Capitals, Amberstone, Tavotek Lab, ClinicalTrial Options, LLC, and Mingruizhiyao. L.Z. holds shares at Amberstone, Alphamab, Cellaration, and Mingruizhiyao.

E.M.J. reports other support from Abmetra and Adventris; personal fees from Dragonfly, Neuvogen, Surge Tx, Mestag, and HDTbio; and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. E.M.J. is a founder of and holds equity in Adventris Pharmaceuticals. She also serves as a consultant to the entity. Further, Adventris Pharmaceuticals has licensed a technology described in this study from the Johns Hopkins University. As a result of that agreement, E.M.J. and the University are entitled to royalty distributions related to technology described in the study discussed in this publication. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. A.J.E.'s spouse is an employee of Immunocore. A.J.E. has unlicensed patents and patent applications in cancer and autoimmunity, and none of them closely relate to the topic of this paper. N.Z. is a consultant for Genentech and Adventris Pharmaceuticals and receives other support from Adventris Pharmaceuticals.

L.M.C. has received reagent support from Cell Signaling Technologies, SynDax Pharmaceuticals, Inc., ZielBio, Inc., and HiberCell, Inc.; holds sponsored research agreements with Prospect Creek Foundation; receives grant support from Susan G. Komen Foundation, National Foundation for Cancer Research, and the National Cancer Institute; and is on the advisory board of Carisma Therapeutics, Inc., CytomX Therapeutics, Inc., Kineta, Inc., HiberCell, Inc., Cell Signaling Technologies, Inc., Alkermes, Inc., NextCure, Guardian Bio, Dispatch Biotherapeutics, AstraZeneca Partner of Choice Network (OHSU Site Leader), Genenta Sciences, Pio Therapeutics Pty Ltd., and Lustgarten Foundation for Pancreatic Cancer Research Therapeutics Working Group.

E.J.F. was on the scientific advisory board of Resistance Bio/Viosera Therapeutics, a paid consultant for Merck and Mestag, and received research funds from Abbvie Inc. and Roche/Genentech outside the submitted work.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

● KEY RESOURCES TABLE

● METHOD DETAILS

- Simulation Methods
- Hypothesis grammar
- Experimental details

● QUANTIFICATION AND STATISTICAL ANALYSIS

- Model initialization from simulated distributions of cellular states and from multi-omics data
- Spatial transcriptomics data of PDAC tumors
- Deriving a metric to quantify the invasiveness of in silico tumor spheroids over time from in silico simulation (PhysiCell model output)
- Single-cell RNA-seq of PDAC tumors as a reference dataset to initialize estimates of immune populations in ABM simulations of treatment effects
- Allen Brain Atlas⁵³ data as a reference dataset to calibrate parameters of an ABM of cortical development

● EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.cell.2025.06.048>.

Received: November 3, 2023

Revised: February 21, 2025

Accepted: June 30, 2025

REFERENCES

1. Stein-O'Brien, G.L., Le, D.T., Jaffee, E.M., Fertig, E.J., and Zaidi, N. (2023). Converging on a Cure: The Roads to Predictive Immunotherapy. *Cancer Discov.* 13, 1053–1057. <https://doi.org/10.1158/2159-8290.CD-23-0277>.
2. Saelens, W., Cannoodt, R., Todorov, H., and Saeys, Y. (2019). A comparison of single-cell trajectory inference methods. *Nat. Biotechnol.* 37, 547–554. <https://doi.org/10.1038/s41587-019-0071-9>.
3. Fertig, E.J., Jaffee, E.M., Macklin, P., Stearns, V., and Wang, C. (2021). Forecasting cancer: from precision to predictive medicine. *Med* 2, 1004–1010. <https://doi.org/10.1016/j.medj.2021.08.007>.
4. Ding, J., Sharon, N., and Bar-Joseph, Z. (2022). Temporal modelling using single-cell transcriptomics. *Nat. Rev. Genet.* 23, 355–368. <https://doi.org/10.1038/s41576-021-00444-7>.
5. Qiu, X., Zhang, Y., Martin-Rufino, J.D., Weng, C., Hosseinzadeh, S., Yang, D., Pogson, A.N., Hein, M.Y., Hoi Joseph Min, K., Wang, L., et al. (2022). Mapping transcriptomic vector fields of single cells. *Cell* 185, 690–711.e45. <https://doi.org/10.1016/j.cell.2021.12.045>.
6. Erbe, R., Stein-O'Brien, G., and Fertig, E.J. (2023). Transcriptomic forecasting with neural ordinary differential equations. *Patterns (N Y)* 4, 100793. <https://doi.org/10.1016/j.patter.2023.100793>.
7. Materi, W., and Wishart, D.S. (2007). Computational systems biology in cancer: modeling methods and applications. *Gene Regul. Syst. Bio.* 1, 91–110. <https://doi.org/10.1177/117762500700100010>.
8. Metzcar, J., Wang, Y.F., Heiland, R., and Macklin, P. (2019). A Review of Cell-Based Computational Modeling in Cancer Biology. *Jco Clin. Cancer Inform.* 3, 1–13. <https://doi.org/10.1200/CCI.18.00069>.
9. Vodovotz, Y., and An, G. (2014). Translational Systems Biology (Academic Press) <https://doi.org/10.1016/c2012-0-00091-9>.
10. Vodovotz, Y., and An, G. (2019). Agent-based models of inflammation in translational systems biology: A decade later. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 11, e1460. <https://doi.org/10.1002/wsbm.1460>.
11. An, G., Mi, Q., Dutta-Moscato, J., and Vodovotz, Y. (2009). Agent-based models in translational systems biology. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 1, 159–171. <https://doi.org/10.1002/wsbm.45>.

12. An, G. (2008). Introduction of an agent-based multi-scale modular architecture for dynamic knowledge representation of acute inflammation. *Theor. Biol. Med. Model.* 5, 11. <https://doi.org/10.1186/1742-4682-5-11>.
13. Scott, J.G., Fletcher, A.G., Anderson, A.R.A., and Maini, P.K. (2016). Spatial Metrics of Tumour Vascular Organisation Predict Radiation Efficacy in a Computational Model. *PLoS Comput. Biol.* 12, e1004712. <https://doi.org/10.1371/journal.pcbi.1004712>.
14. Bozic, I., Reiter, J.G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y.S., Yaqubie, A., Kelly, N., Le, D.T., et al. (2013). Evolutionary dynamics of cancer in response to targeted combination therapy. *eLife* 2, e00747. <https://doi.org/10.7554/eLife.00747>.
15. Cavenee, W.K., Dryja, T.P., Phillips, R.A., Benedict, W.F., Godbout, R., Gallie, B.L., Murphree, A.L., Strong, L.C., and White, R.L. (1983). Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* 305, 779–784. <https://doi.org/10.1038/305779a0>.
16. Diaz, L.A., Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 486, 537–540. <https://doi.org/10.1038/nature11219>.
17. Frank, S.A., Iwasa, Y., and Nowak, M.A. (2003). Patterns of cell division and the risk of cancer. *Genetics* 163, 1527–1532. <https://doi.org/10.1093/genetics/163.4.1527>.
18. Jones, S., Chen, W.D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal, T., Traulsen, A., Nowak, M.A., Siegel, C., Velculescu, V.E., et al. (2008). Comparative lesion sequencing provides insights into tumor evolution. *Proc. Natl. Acad. Sci. USA* 105, 4283–4288. <https://doi.org/10.1073/pnas.0712345105>.
19. Knudson, A.G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. *Proc. Natl. Acad. Sci. USA* 68, 820–823. <https://doi.org/10.1073/pnas.68.4.820>.
20. Komarova, N.L., and Wodarz, D. (2005). Drug resistance in cancer: principles of emergence and prevention. *Proc. Natl. Acad. Sci. USA* 102, 9714–9719. <https://doi.org/10.1073/pnas.0501870102>.
21. Leder, K., Pitter, K., LaPlant, Q., Hambardzumyan, D., Ross, B.D., Chan, T.A., Holland, E.C., and Michor, F. (2014). Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. *Cell* 156, 603–616. <https://doi.org/10.1016/j.cell.2013.12.029>.
22. Lenaerts, T., Pacheco, J.M., Traulsen, A., and Dingli, D. (2010). Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. *Haematologica* 95, 900–907. <https://doi.org/10.3324/haematol.2009.015271>.
23. Sanga, S., Sinek, J.P., Frieboes, H.B., Ferrari, M., Fruehauf, J.P., and Cristini, V. (2006). Mathematical modeling of cancer progression and response to chemotherapy. *Expert Rev. Anticancer Ther.* 6, 1361–1376. <https://doi.org/10.1586/14737140.6.10.1361>.
24. Sherratt, J.A., and Nowak, M.A. (1992). Oncogenes, anti-oncogenes and the immune response to cancer: a mathematical model. *Proc. Biol. Sci.* 248, 261–271. <https://doi.org/10.1098/rspb.1992.0071>.
25. Swanson, K.R., Alvord, E.C., Jr., and Murray, J.D. (2002). Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. *Br. J. Cancer* 86, 14–18. <https://doi.org/10.1038/sj.bjc.6600021>.
26. Lu, Y., Ng, A.H.C., Chow, F.E., Everson, R.G., Helmink, B.A., Tetzlaff, M. T., Thakur, R., Wargo, J.A., Cloughesy, T.F., Prins, R.M., et al. (2021). Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. *Nat. Commun.* 12, 4031. <https://doi.org/10.1038/s41467-021-24293-4>.
27. Pereira, E.J., Burns, J.S., Lee, C.Y., Marohl, T., Calderon, D., Wang, L., Atkins, K.A., Wang, C.C., and Janes, K.A. (2020). Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies. *Sci. Signal.* 13, eaba4200. <https://doi.org/10.1126/scisignal.aba4200>.
28. Kim, M., Park, J., Bouhaddou, M., Kim, K., Rojic, A., Modak, M., Soucheray, M., McGregor, M.J., O'Leary, P., Wolf, D., et al. (2021). A protein interaction landscape of breast cancer. *Science* 374, eabf3066. <https://doi.org/10.1126/science.abf3066>.
29. Stahlberg, E.A., Abdel-Rahman, M., Aguilar, B., Asadpoure, A., Beckman, R.A., Borkon, L.L., Bryan, J.N., Cebulla, C.M., Chang, Y.H., Chatterjee, A., et al. (2022). Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. *Front. Digit. Health* 4, 1007784. <https://doi.org/10.3389/fdgth.2022.1007784>.
30. Laubenbacher, R., Niarakis, A., Helikar, T., An, G., Shapiro, B., Malik-Sheriff, R.S., Sego, T.J., Knapp, A., Macklin, P., and Glazier, J.A. (2022). Building digital twins of the human immune system: toward a roadmap. *NPJ Digit. Med.* 5, 64. <https://doi.org/10.1038/s41746-022-00610-z>.
31. Hernandez-Boussard, T., Macklin, P., Greenspan, E.J., Gryshuk, A.L., Stahlberg, E., Syeda-Mahmood, T., and Shmulevich, I. (2021). Digital twins for predictive oncology will be a paradigm shift for precision cancer care. *Nat. Med.* 27, 2065–2066. <https://doi.org/10.1038/s41591-021-01558-5>.
32. Madhavan, S., Beckman, R.A., McCoy, M.D., Pishvaian, M.J., Brody, J. R., and Macklin, P. (2021). Envisioning the future of precision oncology trials. *Nat. Cancer* 2, 9–11. <https://doi.org/10.1038/s43018-020-00163-8>.
33. An, G. (2004). In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling. *Crit. Care Med.* 32, 2050–2060. <https://doi.org/10.1097/01.ccm.0000139707.13729.7d>.
34. Saint-Pierre, P., and Savy, N. (2023). Agent-based modeling in medical research, virtual baseline generator and change in patients' profile issue. *Int. J. Biostat.* 19, 333–349. <https://doi.org/10.1515/ijb-2022-0112>.
35. Cosgrove, J., Butler, J., Alden, K., Read, M., Kumar, V., Cucurull-Sanchez, L., Timmis, J., and Coles, M. (2015). Agent-Based Modeling in Systems Pharmacology. *CPT Pharmacometrics Syst. Pharmacol.* 4, 615–629. <https://doi.org/10.1002/psp4.12018>.
36. Norton, K.A., Gong, C., Jamalian, S., and Popel, A.S. (2019). Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. *Processes (Basel)* 7, 37. <https://doi.org/10.3390/pr7010037>.
37. Rockne, R.C., Hawkins-Daarud, A., Swanson, K.R., Sluka, J.P., Glazier, J.A., Macklin, P., Hormuth, D.A., Jarrett, A.M., Lima, E.A.B.F., Tinsley Oden, J., et al. (2019). The 2019 mathematical oncology roadmap. *Phys. Biol.* 16, 041005. <https://doi.org/10.1088/1478-3975/ab1a09>.
38. L Rocha, H.L., Aguilar, B., Getz, M., Shmulevich, I., and Macklin, P. (2024). A multiscale model of immune surveillance in micrometastases gives insights on cancer patient digital twins. *npj Syst. Biol. Appl.* 10, 144. <https://doi.org/10.1038/s41540-024-00472-z>.
39. Ozik, J., Collier, N., Heiland, R., An, G., and Macklin, P. (2019). Learning-accelerated discovery of immune-tumour interactions. *Mol. Syst. Des. Eng.* 4, 747–760. <https://doi.org/10.1039/c9me00036d>.
40. Ozik, J., Collier, N., Wozniak, J.M., Macal, C., Cockrell, C., Friedman, S. H., Ghaffarizadeh, A., Heiland, R., An, G., and Macklin, P. (2018). High-throughput cancer hypothesis testing with an integrated PhysiCell-EMEWs workflow. *BMC Bioinformatics* 19, 483. <https://doi.org/10.1186/s12859-018-2510-x>.
41. Mirams, G.R., Arthurs, C.J., Bernabeu, M.O., Bordas, R., Cooper, J., Corrias, A., Davit, Y., Dunn, S.J., Fletcher, A.G., Harvey, D.G., et al. (2013). Chaste: an open source C++ library for computational physiology and biology. *PLoS Comput. Biol.* 9, e1002970. <https://doi.org/10.1371/journal.pcbi.1002970>.
42. Kang, S., Kahan, S., McDermott, J., Flann, N., and Shmulevich, I. (2014). Biocellion: accelerating computer simulation of multicellular biological system models. *Bioinformatics* 30, 3101–3108. <https://doi.org/10.1093/bioinformatics/btu498>.
43. Swat, M.H., Thomas, G.L., Belmonte, J.M., Shirinifard, A., Hmeljak, D., and Glazier, J.A. (2012). Multi-scale modeling of tissues using

- CompuCell3D. *Methods Cell Biol.* **110**, 325–366. <https://doi.org/10.1016/B978-0-12-388403-9.00013-8>.
44. Breitwieser, L., Hesam, A., de Montigny, J., Vavourakis, V., Iosif, A., Jennings, J., Kaiser, M., Manca, M., Di Meglio, A., Al-Ars, Z., et al. (2022). BioDynaMo: a modular platform for high-performance agent-based simulation. *Bioinformatics* **38**, 453–460. <https://doi.org/10.1093/bioinformatics/btab649>.
45. Starrau, J., de Back, W., Brusch, L., and Deutsch, A. (2014). Morpheus: a user-friendly modeling environment for multiscale and multicellular systems biology. *Bioinformatics* **30**, 1331–1332. <https://doi.org/10.1093/bioinformatics/btt772>.
46. Daub, J.T., and Merks, R.M.H. (2015). Cell-based computational modeling of vascular morphogenesis using Tissue Simulation Toolkit. *Methods Mol. Biol.* **1214**, 67–127. https://doi.org/10.1007/978-1-4939-1462-3_6.
47. Ghaffarizadeh, A., Heiland, R., Friedman, S.H., Mumenthaler, S.M., and Macklin, P. (2018). PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. *PLoS Comput. Biol.* **14**, e1005991. <https://doi.org/10.1371/journal.pcbi.1005991>.
48. Bravo, R.R., Baratchart, E., West, J., Schenck, R.O., Miller, A.K., Gallagher, J., Gatenbee, C.D., Basanta, D., Robertson-Tessi, M., and Anderson, A.R.A. (2020). Hybrid Automata Library: A flexible platform for hybrid modeling with real-time visualization. *PLoS Comput. Biol.* **16**, e1007635. <https://doi.org/10.1371/journal.pcbi.1007635>.
49. Germann, P., Marin-Riera, M., and Sharpe, J. (2019). yalla: GPU-Powered Spheroid Models for Mesenchyme and Epithelium. *Cell Syst.* **8**, 261–266.e3. <https://doi.org/10.1016/j.cels.2019.02.007>.
50. Hoehme, S., and Drasdo, D. (2010). A cell-based simulation software for multi-cellular systems. *Bioinformatics* **26**, 2641–2642. <https://doi.org/10.1093/bioinformatics/btq437>.
51. Macklin, P. (2019). Key challenges facing data-driven multicellular systems biology. *GigaScience* **8**, giz127. <https://doi.org/10.1093/giga-science/giz127>.
52. Macklin, P. (2017). When Seeing Isn't Believing: How Math Can Guide Our Interpretation of Measurements and Experiments. *Cell Syst.* **5**, 92–94. <https://doi.org/10.1016/j.cels.2017.08.005>.
53. Sunkin, S.M., Ng, L., Lau, C., Dolbeare, T., Gilbert, T.L., Thompson, C.L., Hawrylycz, M., and Dang, C. (2013). Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system. *Nucleic Acids Res.* **41**, D996–D1008. <https://doi.org/10.1093/nar/gks1042>.
54. Rocha, H.L., Godet, I., Kurtoglu, F., Metzcar, J., Konstantinopoulos, K., Bhojar, S., Gilkes, D.M., and Macklin, P. (2021). A persistent invasive phenotype in post-hypoxic tumor cells is revealed by fate mapping and computational modeling. *iScience* **24**, 102935. <https://doi.org/10.1016/j.isci.2021.102935>.
55. Gonçalves, I.G., Hormuth, D.A., 2nd, Prabhakaran, S., Phillips, C.M., and García-Aznar, J.M. (2023). PhysiCOOL: A generalized framework for model Calibration and Optimization Of modelIng projects. *GigaByte* **2023**, gigabyte77. <https://doi.org/10.46471/gigabyte.77>.
56. Heiland, R., Bergman, D., Lyons, B., Waldow, G., Cass, J., Lima da Rocha, H.L., Ruscone, M., Noël, V., and Macklin, P. (2024). PhysiCell Studio: a graphical tool to make agent-based modeling more accessible. *Gigabyte* **2024**, gigabyte128. <https://doi.org/10.46471/gigabyte.128>.
57. Rocha, H.L. (2025). UQ_PhysiCell. https://github.com/heberlr/UQ_PhysiCell.
58. Wang, Y., Brodin, E., Nishii, K., Frieboes, H.B., Mumenthaler, S.M., Sparks, J.L., and Macklin, P. (2021). Impact of tumor-parenchyma biomechanics on liver metastatic progression: a multi-model approach. *Sci. Rep.* **11**, 1710. <https://doi.org/10.1038/s41598-020-78780-7>.
59. Jagiella, N., Müller, B., Müller, M., Vignon-Clementel, I.E., and Drasdo, D. (2016). Inferring Growth Control Mechanisms in Growing Multi-cellular Spheroids of NSCLC Cells from Spatial-Temporal Image Data. *PLoS Comput. Biol.* **12**, e1004412. <https://doi.org/10.1371/journal.pcbi.1004412>.
60. Hamis, S., Kohandel, M., Dubois, L.J., Yaromina, A., Lambin, P., and Powathil, G.G. (2020). Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape. *PLoS Comput. Biol.* **16**, e1008041. <https://doi.org/10.1371/journal.pcbi.1008041>.
61. Anderson, A.R.A. (2007). A Hybrid Multiscale Model of Solid Tumour Growth and Invasion: Evolution and the Microenvironment. In *Single-Cell-Based Models in Biology and Medicine*, A.R.A. Anderson, M.A.J. Chaplain, and K.A. Rejniak, eds. (Birkhäuser Basel), pp. 3–28. https://doi.org/10.1007/978-3-7643-8123-3_1.
62. Kingsley, J.L., Costello, J.R., Raghunand, N., and Rejniak, K.A. (2021). Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations. *PLoS Comp. Biol.* **17**, e1009206. <https://doi.org/10.1371/journal.pcbi.1009206>.
63. Szabó, A., and Merks, R.M.H. (2013). Cellular Potts Modeling of Tumor Growth, Tumor Invasion, and Tumor Evolution. *Front. Oncol.* **3**, 87. <https://doi.org/10.3389/fonc.2013.00087>.
64. Van Liedekerke, P., Neitsch, J., Johann, T., Alessandri, K., Nassoy, P., and Drasdo, D. (2019). Quantitative cell-based model predicts mechanical stress response of growing tumor spheroids over various growth conditions and cell lines. *PLoS Comp. Biol.* **15**, e1006273. <https://doi.org/10.1371/journal.pcbi.1006273>.
65. McKeown, S.R. (2014). Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. *Br. J. Radiol.* **87**, 20130676. <https://doi.org/10.1259/bjr.20130676>.
66. Godet, I., Shin, Y.J., Ju, J.A., Ye, I.C., Wang, G., and Gilkes, D.M. (2019). Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis. *Nat. Commun.* **10**, 4862. <https://doi.org/10.1038/s41467-019-12412-1>.
67. Guinn, S., Kinny-Köster, B., Tandurella, J.A., Mitchell, J.T., Sidiropoulos, D.N., Loth, M., Lyman, M.R., Pucsek, A.B., Zabransky, D.J., Lee, J.W., et al. (2024). Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma. *Cancer Res.* **84**, 1517–1533. <https://doi.org/10.1158/0008-5472.CAN-23-1660>.
68. Maity, D., Sivakumar, N., Kamat, P., Zamponi, N., Min, C., Du, W., Jayatilaka, H., Johnston, A., Starich, B., Agrawal, A., et al. (2024). Profiling Dynamic Patterns of Single-Cell Motility. *Adv. Sci. (Weinh)* **11**, e2400918. <https://doi.org/10.1002/advsc.202400918>.
69. Zaman, M.H., Trapani, L.M., Sieminski, A.L., Mackellar, D., Gong, H., Kamm, R.D., Wells, A., Lauffenburger, D.A., and Matsudaira, P. (2006). Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. *Proc. Natl. Acad. Sci. USA* **103**, 10889–10894. <https://doi.org/10.1073/pnas.0604460103>.
70. Huang, W., Navarro-Serer, B., Jeong, Y.J., Chianichiano, P., Xia, L., Luchini, C., Veronese, N., Dowiak, C., Ng, T., Trujillo, M.A., et al. (2020). Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. *Cancer Res.* **80**, 2804–2817. <https://doi.org/10.1158/0008-5472.CAN-19-1523>.
71. Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A.S., Ponz-Sarvisé, M., Corbo, V., Oni, T.E., Hearn, S.A., Lee, E.J., et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J. Exp. Med.* **214**, 579–596. <https://doi.org/10.1084/jem.20162024>.
72. Bell, A.T.F., Mitchell, J.T., Kiemen, A.L., Lyman, M., Fujikura, K., Lee, J. W., Coyne, E., Shin, S.M., Nagaraj, S., Deshpande, A., et al. (2024). PanIN and CAF Transitions in Pancreatic Carcinogenesis Revealed with Spatial Data Integration. *Cell Syst.* **15**, 753–769.e5. <https://doi.org/10.1016/j.cels.2024.07.001>.
73. Reichert, M., Bakir, B., Moreira, L., Pitarresi, J.R., Feldmann, K., Simon, L., Suzuki, K., Maddipati, R., Rhim, A.D., Schlitter, A.M., et al. (2018). Regulation of Epithelial Plasticity Determines Metastatic Organotropism

- in Pancreatic Cancer. *Dev. Cell* 45, 696–711.e8. <https://doi.org/10.1016/j.devcel.2018.05.025>.
74. Philipp, L.M., Yesilyurt, U.U., Surrow, A., Künstner, A., Mehdorn, A.S., Hauser, C., Gundlach, J.P., Will, O., Hoffmann, P., Stahmer, L., et al. (2024). Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities. *Cancers (Basel)* 16, 686. <https://doi.org/10.3390/cancers16040686>.
75. Carstens, J.L., Yang, S., Correa de Sampaio, P., Zheng, X., Barua, S., McAndrews, K.M., Rao, A., Burks, J.K., Rhim, A.D., and Kalluri, R. (2021). Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. *Cell Rep.* 35, 108990. <https://doi.org/10.1016/j.celrep.2021.108990>.
76. Qiu, B., Yuan, P., Du, X., Jin, H., Du, J., and Huang, Y. (2023). Hypoxia inducible factor-1alpha is an important regulator of macrophage biology. *Heliyon* 9, e17167. <https://doi.org/10.1016/j.heliyon.2023.e17167>.
77. Ke, X., Chen, C., Song, Y., Cai, Q., Li, J., Tang, Y., Han, X., Qu, W., Chen, A., Wang, H., et al. (2019). Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells. *Oncol. Lett.* 18, 5871–5878. <https://doi.org/10.3892/ol.2019.10956>.
78. Rahat, M.A., Bitterman, H., and Lahat, N. (2011). Molecular mechanisms regulating macrophage response to hypoxia. *Front. Immunol.* 2, 45. <https://doi.org/10.3389/fimmu.2011.00045>.
79. Zöphel, D., Angenendt, A., Kaschek, L., Ravichandran, K., Hof, C., Janku, S., Hoth, M., and Lis, A. (2022). Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8(+) T cells boost cancer cell elimination. *Aging Cell* 21, e13668. <https://doi.org/10.1111/ace1.13668>.
80. Lelliott, E.J., Ramsbottom, K.M., Dowling, M.R., Shembrey, C., Noori, T., Kearney, C.J., Michie, J., Parish, I.A., Jordan, M.A., Baxter, A.G., et al. (2022). NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation. *Front. Immunol.* 13, 931630. <https://doi.org/10.3389/fimmu.2022.931630>.
81. Valitutti, S., Coombs, D., and Dupré, L. (2010). The space and time frames of T cell activation at the immunological synapse. *FEBS Lett.* 584, 4851–4857. <https://doi.org/10.1016/j.febslet.2010.10.010>.
82. Ortega-Carrion, A., and Vicente-Manzanares, M. (2016). Concerning immune synapses: a spatiotemporal timeline F1000 Faculty Rev-418. *F1000Res* 5. <https://doi.org/10.12688/f1000research.7796.1>.
83. Koh, C.H., Lee, S., Kwak, M., Kim, B.S., and Chung, Y. (2023). CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. *Exp. Mol. Med.* 55, 2287–2299. <https://doi.org/10.1038/s12276-023-01105-x>.
84. DeNardo, D.G., Barreto, J.B., Andreu, P., Vazquez, L., Tawfik, D., Kolhatkar, N., and Coussens, L.M. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell* 16, 91–102. <https://doi.org/10.1016/j.ccr.2009.06.018>.
85. Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., and Ueno, N.T. (2012). Role of epidermal growth factor receptor in breast cancer. *Breast Cancer Res. Treat.* 136, 331–345. <https://doi.org/10.1007/s10549-012-2289-9>.
86. Price, J.T., Tiganis, T., Agarwal, A., Djakiew, D., and Thompson, E.W. (1999). Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. *Cancer Res.* 59, 5475–5478.
87. Shiao, S.L., Ruffell, B., DeNardo, D.G., Faddegon, B.A., Park, C.C., and Coussens, L.M. (2015). TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. *Cancer Immunol. Res.* 3, 518–525. <https://doi.org/10.1158/2326-6066.CIR-14-0232>.
88. Heumann, T., Judkins, C., Li, K., Lim, S.J., Hoare, J., Parkinson, R., Cao, H., Zhang, T., Gai, J., Celiker, B., et al. (2023). A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. *Nat. Commun.* 14, 3650. <https://doi.org/10.1038/s41467-023-39196-9>.
89. Montagne, J.M., Mitchell, J.T., Tandurella, J.A., Christenson, E.S., Danilova, L.V., Deshpande, A., Loth, M., Sidiropoulos, D.N., Davis-Marcisak, E., Bergman, D.R., et al. (2025). CD137 agonism enhances anti-PD1 induced activation of expanded CD8(+) T cell clones in a neoadjuvant pancreatic cancer clinical trial. *iScience* 28, 111569. <https://doi.org/10.1016/j.isci.2024.111569>.
90. Jaffee, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. *J. Clin. Oncol.* 19, 145–156. <https://doi.org/10.1200/JCO.2001.19.1.145>.
91. Li, K., Tandurella, J.A., Gai, J., Zhu, Q., Lim, S.J., Thomas, D.L., 2nd, Xia, T., Mo, G., Mitchell, J.T., Montagne, J., et al. (2022). Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. *Cancer Cell* 40, 1374–1391.e7. <https://doi.org/10.1016/j.ccell.2022.10.001>.
92. Steele, N.G., Carpenter, E.S., Kemp, S.B., Sirihorachai, V.R., The, S., Delrosario, L., Lazarus, J., Amir, E.D., Gunchick, V., Espinoza, C., et al. (2020). Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. *Nat. Cancer* 1, 1097–1112. <https://doi.org/10.1038/s43018-020-00121-4>.
93. Lutz, E.R., Wu, A.A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014). Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. *Cancer Immunol. Res.* 2, 616–631. <https://doi.org/10.1158/2326-6066.CIR-14-0027>.
94. Desikan, R.S., and Barkovich, A.J. (2016). Malformations of cortical development. *Ann. Neurol.* 80, 797–810. <https://doi.org/10.1002/ana.24793>.
95. Ruscone, M., Checcoli, A., Heiland, R., Barillot, E., Macklin, P., Calzone, L., and Noël, V. (2024). Building multiscale models with PhysiBoSS, an agent-based modeling tool. *Brief. Bioinform.* 25, bbae509. <https://doi.org/10.1093/bib/bbae509>.
96. Friedman, S.H., Anderson, A.R.A., Bortz, D.M., Fletcher, A.G., Frieboes, H.B., Ghaffarizadeh, A., Grimes, D.R., Hawkins-Daarud, A., Hoehme, S., Juarez, E.F., et al. (2016). MultiCellDS: a community-developed standard for curating microenvironment-dependent multicellular data. Preprint at bioRxiv. <https://doi.org/10.1101/090456>.
97. Arulraj, T., Wang, H., Ippolito, A., Zhang, S., Fertig, E.J., and Popel, A.S. (2024). Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology. *Brief. Bioinform.* 25, bbae131. <https://doi.org/10.1093/bib/bbae131>.
98. Ponce-de-Leon, M., Montagud, A., Noël, V., Meert, A., Pradas, G., Barillot, E., Calzone, L., and Valencia, A. (2023). PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks. *NPJ Syst. Biol. Appl.* 9, 54. <https://doi.org/10.1038/s41540-023-00314-4>.
99. Letort, G., Montagud, A., Stoll, G., Heiland, R., Barillot, E., Macklin, P., Zinoviyev, A., and Calzone, L. (2019). PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signalling. *Bioinformatics* 35, 1188–1196. <https://doi.org/10.1093/bioinformatics/bty766>.
100. Johnson, B.E., Creason, A.L., Stommel, J.M., Keck, J.M., Parmar, S., Betts, C.B., Blucher, A., Boniface, C., Bucher, E., Burlingame, E., et al. (2022). An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. *Cell Rep. Med.* 3, 100525. <https://doi.org/10.1016/j.xcrm.2022.100525>.

101. Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J.E., Ashenberg, O., Cerami, E., Coffey, R.J., Demir, E., et al. (2020). The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell* 181, 236–249. <https://doi.org/10.1016/j.cell.2020.03.053>.
102. Lukaszewicz, A., Savatier, P., Cortay, V., Giroud, P., Huissoud, C., Berland, M., Kennedy, H., and Dehay, C. (2005). G1 phase regulation, area-specific cell cycle control, and cytoarchitectonics in the primate cortex. *Neuron* 47, 353–364. <https://doi.org/10.1016/j.neuron.2005.06.032>.
103. Dehay, C., and Kennedy, H. (2007). Cell-cycle control and cortical development. *Nat. Rev. Neurosci.* 8, 438–450. <https://doi.org/10.1038/nrn2097>.
104. (2024). PhysiCell, Version 1.14.1 (Cell Press). <https://github.com/MathCancer/PhysiCell/releases/tag/1.14.1>.
105. Madhavan, K., Zentner, L., Farnsworth, V., Shivarajapura, S., Zentner, M., Denny, N., and Klimeck, G. (2013). nanoHUB.org: cloud-based services for nanoscale modeling, simulation, and education. *Nanotechnol. Rev.* 2, 107–117. <https://doi.org/10.1515/ntrev-2012-0043>.
106. Kiemen, A.L., Braxton, A.M., Grahn, M.P., Han, K.S., Babu, J.M., Reichel, R., Jiang, A.C., Kim, B., Hsu, J., Amoa, F., et al. (2022). CODA: quantitative 3D reconstruction of large tissues at cellular resolution. *Nat. Methods* 19, 1490–1499. <https://doi.org/10.1038/s41592-022-01650-9>.
107. Sharma, G., Colantuoni, C., Goff, L.A., Fertig, E.J., and Stein-O'Brien, G. (2020). projectR: an R/Bioconductor package for transfer learning via PCA, NMF, correlation and clustering. *Bioinformatics* 36, 3592–3593. <https://doi.org/10.1093/bioinformatics/btaa183>.
108. Johnson, J., Tsang, A., Mitchell, J.T., Davis-Marcisak, E., Sherman, T., Liefeld, T., Loth, M., Goff, L.A., Zimmerman, J., Kinny-Köster, B., et al. (2022). Inferring cellular and molecular processes in single-cell data with non-negative matrix factorization using Python, R, and GenePattern Notebook implementations of CoGAPS. *Nat. Protoc.* 18, 3690–3731. <https://doi.org/10.1038/s41596-023-00892-x>.
109. Kinny-Köster, B., Guinn, S., Tandurella, J.A., Mitchell, J.T., Sidiropoulos, D.N., Loth, M., Lyman, M.R., Pucsek, A.B., Seppälä, T.T., Cherry, C., et al. (2022). Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture. Preprint at bioRxiv. <https://doi.org/10.1101/2022.07.14.500096>.
110. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. *Cell* 184, 3573–3587.e29. <https://doi.org/10.1016/j.cell.2021.04.048>.
111. Heiland, R., Mishler, D., Zhang, T., Bower, E., and Macklin, P. (2019). xml2jupyter: Mapping parameters between XML and Jupyter widgets. *J. Open Source Softw.* 4, 4. <https://doi.org/10.21105/joss.01408>.
112. Saxena, G., Ponce-de-Leon, M., Montagud, A., Vicente Dorca, D., and Valencia, A. (2021). BioFVM-X: An MPI+OpenMP 3-D Simulator for Biological Systems. In *Computational Methods in Systems Biology*, E. Cinquemani and L. Paulevé, eds. (Springer International Publishing), pp. 266–279. https://doi.org/10.1007/978-3-030-85633-5_18.
113. Ghaffarizadeh, A., Friedman, S.H., and Macklin, P. (2016). BioFVM: an efficient, parallelized diffusive transport solver for 3-D biological simulations. *Bioinformatics* 32, 1256–1258. <https://doi.org/10.1093/bioinformatics/btv730>.
114. Sundus, A., Kurtoglu, F., Konstantinopoulos, K., Chen, M., Willis, D., Heiland, R., and Macklin, P. (2022). PhysiCell training apps: Cloud hosted open-source apps to learn cell-based simulation software. Preprint at bioRxiv. <https://doi.org/10.1101/2022.06.24.497566>.
115. Wortel, I.M., and Textor, J. (2021). Artistoo, a library to build, share, and explore simulations of cells and tissues in the web browser. *eLife* 10, e61288. <https://doi.org/10.7554/eLife.61288>.
116. Heiland, R., and Macklin, P. (2023) PhysiCell Studio Cloud, [Version 1.0]. <https://nanohub.org/tools/pstudio>.
117. Sluka, J.P., Shirinifard, A., Swat, M., Cosmanescu, A., Heiland, R.W., and Glazier, J.A. (2014). The cell behavior ontology: describing the intrinsic biological behaviors of real and model cells seen as active agents. *Bioinformatics* 30, 2367–2374. <https://doi.org/10.1093/bioinformatics/btu210>.
118. Jenner, A.L., Smalley, M., Goldman, D., Goins, W.F., Cobbs, C.S., Puchalski, R.B., Chioccia, E.A., Lawler, S., Macklin, P., Goldman, A., et al. (2022). Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. *iScience* 25, 104395. <https://doi.org/10.1016/j.isci.2022.104395>.
119. Islam, M.A., Getz, M., Macklin, P., and Ford Versypt, A.N.F. (2023). An agent-based modeling approach for lung fibrosis in response to COVID-19. *PLoS Comput. Biol.* 19, e1011741. <https://doi.org/10.1371/journal.pcbi.1011741>.
120. Getz, M., Wang, Y., An, G., Asthana, M., Becker, A., Cockrell, C., Collier, N., Craig, M., Davis, C.L., Faeder, J.R., et al. (2021). Iterative community-driven development of a SARS-CoV-2 tissue simulator. Preprint at bioRxiv. <https://doi.org/10.1101/2020.04.02.019075>.
121. Risner, K.H., Tieu, K.V., Wang, Y., Bakovic, A., Alem, F., Bhalla, N., Nathan, S., Conway, D.E., Macklin, P., and Narayanan, A. (2020). Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. Preprint at bioRxiv. <https://doi.org/10.1101/2020.08.12.246389>.
122. Metzcar, J., Duggan, B.S., Fischer, B., Murphy, M., Heiland, R., and Macklin, P. (2025). A Simple Framework for Agent-Based Modeling with Extracellular Matrix. *Bull. Math. Biol.* 87, 43. <https://doi.org/10.1007/s11538-024-01408-8>.
123. Hoehme, S., Friebe, A., Hammad, S., Drasdo, D., and Hengstler, J.G. (2017). Creation of Three-Dimensional Liver Tissue Models from Experimental Images for Systems Medicine. *Methods Mol. Biol.* 1506, 319–362. https://doi.org/10.1007/978-1-4939-6506-9_22.
124. Finley, S.D., and Popel, A.S. (2013). Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. *J. Natl. Cancer Inst.* 105, 802–811. <https://doi.org/10.1093/jnci/djt093>.
125. Swan, A., Hillen, T., Bowman, J.C., and Murtha, A.D. (2018). A Patient-Specific Anisotropic Diffusion Model for Brain Tumour Spread. *Bull. Math. Biol.* 80, 1259–1291. <https://doi.org/10.1007/s11538-017-0271-8>.
126. Chaplain, M.A., Graziano, L., and Preziosi, L. (2006). Mathematical modelling of the loss of tissue compression responsiveness and its role in solid tumour development. *Math. Med. Biol.* 23, 197–229. <https://doi.org/10.1093/imammb/dql009>.
127. Alarcón, T., Byrne, H.M., and Maini, P.K. (2003). A cellular automaton model for tumour growth in inhomogeneous environment. *J. Theor. Biol.* 225, 257–274. [https://doi.org/10.1016/s0022-5193\(03\)00244-3](https://doi.org/10.1016/s0022-5193(03)00244-3).
128. Scott, J.G., Basanta, D., Anderson, A.R.A., and Gerlee, P. (2013). A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth. *J. R. Soc. Interface* 10, 20130011. <https://doi.org/10.1098/rsif.2013.0011>.
129. Kaznatcheev, A., Vander Velde, R., Scott, J.G., and Basanta, D. (2017). Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature. *Br. J. Cancer* 116, 785–792. <https://doi.org/10.1038/bjc.2017.5>.
130. Poleszczuk, J., Hahnfeldt, P., and Enderling, H. (2014). Biphasic modulation of cancer stem cell-driven solid tumour dynamics in response to re-activated replicative senescence. *Cell Prolif.* 47, 267–276. <https://doi.org/10.1111/cpr.12101>.
131. Powathil, G.G., Adamson, D.J.A., and Chaplain, M.A.J. (2013). Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational

- model. *PLoS Comput. Biol.* 9, e1003120. <https://doi.org/10.1371/journal.pcbi.1003120>.
132. Hamis, S., Nithiarasu, P., and Powathil, G.G. (2018). What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance. *J. Theor. Biol.* 454, 253–267. <https://doi.org/10.1016/j.jtbi.2018.06.014>.
133. Fortuna, I., Perrone, G.C., Krug, M.S., Susin, E., Belmonte, J.M., Thomas, G.L., Glazier, J.A., and de Almeida, R.M.C. (2020). CompuCell3D Simulations Reproduce Mesenchymal Cell Migration on Flat Substrates. *Biophys. J.* 118, 2801–2815. <https://doi.org/10.1016/j.bpj.2020.04.024>.
134. Dunn, S.J., Appleton, P.L., Nelson, S.A., Näthke, I.S., Gavaghan, D.J., and Osborne, J.M. (2012). A two-dimensional model of the colonic crypt accounting for the role of the basement membrane and pericryptal fibroblast sheath. *PLoS Comput. Biol.* 8, e1002515. <https://doi.org/10.1371/journal.pcbi.1002515>.
135. Glen, C.M., Kemp, M.L., and Voit, E.O. (2019). Agent-based modeling of morphogenetic systems: Advantages and challenges. *PLoS Comput. Biol.* 15, e1006577. <https://doi.org/10.1371/journal.pcbi.1006577>.
136. Dokmegan, J., Yap, M.H., Han, L., Cavaliere, M., and Doursat, R. (2021). Computational modelling unveils how epiblast remodelling and positioning rely on trophectoderm morphogenesis during mouse implantation. *PLoS One* 16, e0254763. <https://doi.org/10.1371/journal.pone.0254763>.
137. Camacho-Gómez, D., García-Aznar, J.M., and Gómez-Benito, M.J. (2022). A 3D multi-agent-based model for lumen morphogenesis: the role of the biophysical properties of the extracellular matrix. *Eng. Comput.* 38, 4135–4149. <https://doi.org/10.1007/s00366-022-01654-1>.
138. Cess, C.G., and Finley, S.D. (2020). Multi-scale modeling of macrophage-T cell interactions within the tumor microenvironment. *PLoS Comp. Biol.* 16, e1008519. <https://doi.org/10.1371/journal.pcbi.1008519>.
139. Ruiz-Martinez, A., Gong, C., Wang, H., Sové, R.J., Mi, H., Kimko, H., and Popel, A.S. (2022). Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. *PLOS Comput. Biol.* 18, e1010254. <https://doi.org/10.1371/journal.pcbi.1010254>.
140. Ni, C., and Lu, T. (2022). Individual-Based Modeling of Spatial Dynamics of Chemotactic Microbial Populations. *ACS Synth. Biol.* 11, 3714–3723. <https://doi.org/10.1021/acssynbio.2c00322>.
141. Hellweger, F.L., and Bucci, V. (2009). A bunch of tiny individuals—Individual-based modeling for microbes. *Ecol. Modell.* 220, 8–22. <https://doi.org/10.1016/j.ecolmodel.2008.09.004>.
142. Osińska, I., Popko, K., and Demkow, U. (2014). Perforin: an important player in immune response. *Cent. Eur. J. Immunol.* 39, 109–115. <https://doi.org/10.5114/ceji.2014.42135>.
143. Farhood, B., Najafi, M., and Mortezaee, K. (2019). CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. *J. Cell. Physiol.* 234, 8509–8521. <https://doi.org/10.1002/jcp.27782>.
144. Raskov, H., Orhan, A., Christensen, J.P., and Gögenur, I. (2021). Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. *Br. J. Cancer* 124, 359–367. <https://doi.org/10.1038/s41416-020-01048-4>.
145. Meyer, C.T., Wooten, D.J., Paudel, B.B., Bauer, J., Hardeman, K.N., Westover, D., Lovly, C.M., Harris, L.A., Tyson, D.R., and Quaranta, V. (2019). Quantifying Drug Combination Synergy along Potency and Efficacy Axes. *Cell Syst.* 8, 97–108.e16. <https://doi.org/10.1016/j.cels.2019.01.003>.
146. Wooten, D.J., Meyer, C.T., Lubbock, A.L.R., Quaranta, V., and Lopez, C. F. (2021). MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. *Nat. Commun.* 12, 4607. <https://doi.org/10.1038/s41467-021-24789-z>.
147. Barrett, T., Wilhite, S.E., Ledoux, P., Evangelista, C., Kim, I.F., Thomashefsky, M., Marshall, K.A., Phillippy, K.H., Sherman, P.M., Holko, M., et al. (2013). NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res.* 41, D991–D995. <https://doi.org/10.1093/nar/gks1193>.
148. Edgar, R., Domrachev, M., and Lash, A.E. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 30, 207–210. <https://doi.org/10.1093/nar/30.1.207>.
149. Berens, E.B., Holy, J.M., Riegel, A.T., and Wellstein, A. (2015). A Cancer Cell Spheroid Assay to Assess Invasion in a 3D Setting. *J. Vis. Exp.* 105, 53409. <https://doi.org/10.3791/53409>.
150. Lim, G.J., Kang, S.J., and Lee, J.Y. (2020). Novel invasion indices quantify the feed-forward facilitation of tumor invasion by macrophages. *Sci. Rep.* 10, 718. <https://doi.org/10.1038/s41598-020-57517-6>.
151. Bergman, D. (2024). abm-spheroid-invasiveness (v0.1.0-beta). <https://github.com/emcramer/abm-spheroid-invasiveness/releases/tag/v0.1.0-beta>.
152. Pullan, S., Wilson, J., Metcalfe, A., Edwards, G.M., Gøberdhan, N., Tilly, J., Hickman, J.A., Dive, C., and Streuli, C.H. (1996). Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. *J. Cell Sci.* 109, 631–642. <https://doi.org/10.1242/jcs.109.3.631>.
153. Debnath, J., Muthuswamy, S.K., and Brugge, J.S. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 30, 256–268. [https://doi.org/10.1016/S1046-2023\(03\)00032-x](https://doi.org/10.1016/S1046-2023(03)00032-x).
154. Padmanaban, V., Grasset, E.M., Neumann, N.M., Fraser, A.K., Henriët, E., Matsui, W., Tran, P.T., Cheung, K.J., Georgess, D., and Ewald, A.J. (2020). Organotypic culture assays for murine and human primary and metastatic-site tumors. *Nat. Protoc.* 15, 2413–2442. <https://doi.org/10.1038/s41596-020-0335-3>.
155. McLean, I. (2024). Live-Cell Imaging of MCF10A Cells Treated with EGF or PBS. Zenodo. <https://doi.org/10.5281/zenodo.14106341>.
156. Gross, S.M., Dane, M.A., Smith, R.L., Devlin, K.L., McLean, I.C., Derrick, D.S., Mills, C.E., Subramanian, K., London, A.B., Torre, D., et al. (2022). A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses. *Commun. Biol.* 5, 1066. <https://doi.org/10.1038/s42003-022-03975-9>.
157. Jeong, Y.J., Knutsdottir, H., Shojaeian, F., Lerner, M.G., Wissler, M. F., Henriët, E., Ng, T., Datta, S., Navarro-Serer, B., Chianchiano, P., et al. (2023). Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion. *J. Clin. Invest.* 133, e162054. <https://doi.org/10.1172/JCI162054>.
158. Jaffee, E.M., Schutte, M., Gossett, J., Morsberger, L.A., Adler, A.J., Thomas, M., Greden, T.F., Hruban, R.H., Yeo, C.J., and Griffin, C.A. (1998). Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. *Cancer J. Sci. Am.* 4, 194–203.
159. Wu, P.H., Giri, A., Sun, S.X., and Wirtz, D. (2014). Three-dimensional cell migration does not follow a random walk. *Proc. Natl. Acad. Sci. USA.* 111, 3949–3954. <https://doi.org/10.1073/pnas.1318967111>.
160. Wu, P.H., Giri, A., and Wirtz, D. (2015). Statistical analysis of cell migration in 3D using the anisotropic persistent random walk model. *Nat. Protoc.* 10, 517–527. <https://doi.org/10.1038/nprot.2015.030>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological samples		
PDAC tumor specimens	Johns Hopkins Hospital	Not applicable
Patient-derived organoids (PDOs)	This Study	Not applicable
Cancer-associated fibroblasts (CAFs)	This Study	Not applicable
Chemicals, peptides, and recombinant proteins		
Gefitinib	MedChemExpress	Cat#HY-50895
PD153035 inhibitor	Calbiochem	23-449
IBIBX1382 inhibitor	Calbiochem	324832
IL4	PeproTech	214-14
IL13	PeproTech	210-13
IL10	PeproTech	AF-210-10
IFN γ	PeproTech	315-05
LPS	Invitrogen	00-4976
Collagenase A	Roche	11088793001
DNase I	Roche	10104159001
Cultrex BME	R&D Systems	3431-005-01
Recombinant Human EGF Protein, CF	R&D Systems	236-EG
Rat tail collagen type I	Corning	354236
Dispase	Gibco	Cat #17105-041
Collagenase Type II	Gibco	Cat #17101-015
Collagen I (rat-tail)	Corning	Cat #354236
Human EGF	Sigma-Aldrich	E9644
Insulin	Gibco	Cat #12585
Cholera toxin	Sigma-Aldrich	C8052
Bovine Serum Albumin (BSA)	Sigma-Aldrich	A1595
Matrigel	Corning	Cat #: 354236
Critical commercial assays		
Cell tracker	Invitrogen	C7025
Deposited data		
Live-cell imaging from EGF or PBS treated MCF10A cells	Zenodo	https://zenodo.org/records/14106341
Sensitivity analysis simulation data	Zenodo	https://doi.org/10.5281/zenodo.14590311
Experimental models: Cell lines		
Panc10.05	ATCC.org	CRL-2547
hT231	Lab of Dr. David Tuveson	N/A
Mouse: FVB/N-Tg(MMTV-PyVT)634Mul/J	The Jackson Laboratory	Cat#002374;RRID: IMSR_JAX:002374
Cell Line: MCF10A	Gift from Gordon Mills (OHSU)	N/A
Software and algorithms		
NIS-Elements	Nikon Instruments	https://www.microscope.healthcare.nikon.com/products/software/nis-elements
ImageJ	NIH	https://imagej.net/ij/
Baxter Algorithm	https://doi.org/10.1109/TMI.2014.2370951	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
CellPose 2.0	https://doi.org/10.1038/s41592-022-01663-4	N/A
PhysiCell	Ghaffarizadeh et al. (2018) ⁴⁷	http://physicell.org/
PhysiCell Studio	Heiland et al. ⁵⁶	https://nanohub.org/tools/pcstudio
nanoHUB platform	Madhavan et al. ¹⁰⁵	https://nanohub.org/
Computational model in C++	This paper	https://github.com/physicell-models/grammar_samples
Migration speed calibration code	This paper	https://github.com/PhysiCell-Models/grammar_samples/tree/main/experimental_data_analysis/PancCAFAAnalysis
Uncertainty quantification software	This paper	https://github.com/heberlr/UQ_PhysiCell
Spheroid analysis software	This paper	https://github.com/emcramer/abm-spheroid-invasiveness/releases/tag/v0.1.0-beta
CODA	Kiemen et al. ¹⁰⁶	https://doi.org/10.1038/s41592-022-01650-9
ProjectR transfer learning software	Sharma et al. ¹⁰⁷	https://doi.org/10.1093/bioinformatics/btaa183
CoGAPs non-negative matrix factorization for scRNA-seq data	Bell et al. ⁷² , Johnson et al. ¹⁰⁸ , Kinny-Köster et al. ¹⁰⁹	https://doi.org/10.1038/s41596-023-00892-x
Seurat 4.1.0	Hao et al. ¹¹⁰	https://github.com/satijalab/seurat/releases

METHOD DETAILS

Simulation Methods

PhysiCell agent-based modeling framework

PhysiCell⁴⁷ is an open source, agent-based modeling framework written in C++ that can run on a broad variety of desktop platforms, in the cloud,¹¹¹ and on high performance computing resources.^{38–40,112} PhysiCell simulates each cell as an agent with lattice-free position and volume, individual birth and death rates, and motion driven by the balance of mechanical forces and biased random migration. In more recent versions of PhysiCell, agents can also interact with built-in models of phagocytosis, effector attack, fusion, and elastic cell-cell adhesion. PhysiCell is coupled to a reaction-diffusion solver (BioFVM¹¹³) that models secretion and uptake (consumption) of diffusible factors by individual cell agents at their individual positions, as well as diffusion and decay of these substrates through extracellular spaces. PhysiCell bundles its key cell behavioral parameters as a *phenotype object* for simpler representation. Modelers simulate biological hypotheses by writing custom C++ functions that dynamically vary the cell agent's phenotype parameters based on conditions at the cell's position, such as contact with other cells, mechanical pressure, and concentrations and gradients of signaling factors. This paper extends PhysiCell with built-in functions that parse rules written with our grammar to operate on cell phenotypes without writing C++ code.

Installation instructions

PhysiCell Version 1.14.1¹⁰⁴ and later includes a full reference implementation of the grammar and grammar-based simulation modeling, and the specific models in the results are available from https://github.com/physicell-models/grammar_samples. To get a list of all the example models:

```
make list-user-projects
```

To load and compile an example named **myproject**, use

```
make load PROJ=myproject && make
```

Similar to our prior work to create cloud-based training materials¹¹⁴ and cloud-based model dissemination,¹¹¹ and inspired by other recent advances on “zero-install” models,¹¹⁵ we have created a cloud-based version^{56,116} of PhysiCell based on the nanoHUB platform.¹⁰⁵ This cloud implementation allows scientists to create, execute, visualize, and explore grammar-based models interactively in a web browser, without need for programming expertise or software setup. (See documentation and training materials in [Methods S1](#)) The cloud-hosted model is available at <https://nanohub.org/tools/pcstudio>. Alternatively, scientists can download the latest release of the PhysiCell Studio⁵⁶ desktop application at <https://github.com/PhysiCell-Tools/PhysiCell-Studio/releases>. Assuming an executable model has been compiled, the Studio allows interactive creation and editing of rules, running a simulation,

and visualizing results. Refer to the Studio user guide at <https://github.com/PhysiCell-Tools/Studio-Guide/blob/main/README.md> for more information.

Self-guided, hands-on training courses are available at <https://physicell.org/Training.html>. See further details in [Methods S1](#).

Hypothesis grammar

Cell behaviors

To build this grammar, we require clear abstractions of key cell behaviors that frequently occur in multicellular observations and corresponding reference models. In this context, a **cell behavior** is a cell-scale process, such as cycling, death, or phagocytosis. Generally, each behavior can be represented by a small number of continuous phenotypic parameters, describing the rate, magnitude, or frequency of the behavior. In earlier work, Sluka et al. developed the Cell Behavior Ontology (CBO)¹¹⁷ as a controlled vocabulary of individual cell behaviors. More recently, we worked with a multidisciplinary coalition to extend and structure behaviors from the CBO and other sources into MultiCellDS⁹⁶ (multicellular data standard). In particular, this work defined a *cell behavioral phenotype* that collects of biophysical characterizations of a cell's behavior, organized hierarchically by function: cycling, death, volume, mechanics, secretion (including uptake), and motility. Since releasing MultiCellDS as a preprint, we have tested this approach to cell behavior through a variety of agent-based simulation and modeling projects.^{38–40,47,54,58,99,114,118–122} Based upon recent immunologic modeling work,^{38,118–121} we extended phenotype to include cell-cell interactions (phagocytosis, effector attack, and fusion), as well as transitions between cell types (e.g., differentiation, transdifferentiation, and other state changes that persist even when exogenous signals are removed). See [Methods S1](#) for a full description of these cell behaviors, including reference model implementation details in the PhysiCell framework.

Signals

Signals are (typically exogeneous but sometimes internal) stimuli or information that can be interpreted by a cell to drive behavioral or state changes. In the context of mathematical modeling, signals are inputs to constitutive laws or agent rules. We broadly surveyed mathematical and biological models from cancer biology,^{36,61,123–132} tissue morphogenesis,^{123,133–137} immunology,^{36,118–120,138,139} and microbial ecosystems,^{140,141} to generalize classes of inputs to cell behavioral rules, generally including chemical factors, mechanical cues, cell volume (e.g., for volume-based cycle checkpoints), physical contact with cells, live/dead status, current simulation time (for use in triggering events), and accumulated damage (e.g., from effector attack^{142–144}). See [Methods S1](#) for a full description.

Behavioral statements

For any cell type T , we construct simple statements that relate changes in a single behavior B to a signal S : “In T , S increases/decreases B [with optional arguments].” Here B is a well-defined biophysical parameter in our dictionary of behaviors (see [STAR Methods](#) and [Methods S1](#)), S is a well-defined biophysical variable in our dictionary of signals, and optional arguments further specify the mathematical behavior of the responses. For example:

In MCF-7 breast cancer cells, cisplatin increases apoptosis.

In naïve T cells, IL-10 decreases transition to CD8⁺ T cells.

A full description of the grammar, optional arguments, and examples can be found in [Methods S1](#).

Mathematical representation: individual rules

With clearly defined behaviors and signals and the grammar to connect them, we can uniquely map human-interpretable cell hypothesis statements onto mathematical expressions that make the grammar both human interpretable and computable. Each individual rule modulates a single behavioral parameter b as a function of a signal s . Given a response function R , we then mathematically represent the individual rule as a function $b(s)$:

$$b(s) = b_0 + (b_M - b_0)R(s), \quad (1)$$

where b_0 is the base value of the parameter in the absence of signal, and b_M is the maximally changed value of the parameter with large signals. By default, we use sigmoidal (Hill) response functions R , due to their extensive use in signaling network models and pharmacodynamics, as well as their smooth variation between 0 (at no response) and 1 (at maximum response). However, capped linear response functions (varying between 0 and 1) and step functions are also possible ([Figure S2](#)). See [Figure 1C](#) for a typical rule. Full mathematical details and additional detailed examples are available in [Methods S1](#).

Generalized mathematical representation: multiple rules

Our full mathematical formulation allows new hypotheses to be directly added to models without modifying prior hypotheses, making our framing extensible and scalable as new knowledge is acquired. Suppose that a behavior B (with corresponding behavioral parameter b) is controlled by multiple rules subject to promoting (up-regulating) signals u and inhibiting (down-regulating) signals d :

- u_1 increases B (with half-max u_1^* and Hill power p_1)
- u_2 increases B (with half-max u_2^* and Hill power p_2)
- ...
- u_m increases B (with half-max u_m^* and Hill power p_m)
- d_1 decreases B (with half-max d_1^* and Hill power q_1)
- d_2 decreases B (with half-max d_2^* and Hill power q_2)
- ...
- d_n decreases B (with half-max d_n^* and Hill power q_n)

Here, let b_M be the maximum value of the behavior parameter b (under the combined influence of the up-regulating signals $\mathbf{u}$), let b_0 be its base value in the absence of signals, and let b_m be its minimum value (under the combined influence of the down-regulating signals $\mathbf{d}$).

Similar to prior multi-variate response functions,^{145,146} we define the total up response as:

$$U = H_M(\mathbf{u}; \mathbf{u}_{\text{half}}, \mathbf{p}) = \frac{\left(\frac{u_1}{u_1^*}\right)^{p_1} + \left(\frac{u_2}{u_2^*}\right)^{p_2} + \dots + \left(\frac{u_m}{u_m^*}\right)^{p_m}}{1 + \left(\frac{u_1}{u_1^*}\right)^{p_1} + \left(\frac{u_2}{u_2^*}\right)^{p_2} + \dots + \left(\frac{u_m}{u_m^*}\right)^{p_m}} \quad (2)$$

and the total down response as:

$$D = H_M(\mathbf{d}; \mathbf{d}_{\text{half}}, \mathbf{q}) = \frac{\left(\frac{d_1}{d_1^*}\right)^{q_1} + \left(\frac{d_2}{d_2^*}\right)^{q_2} + \dots + \left(\frac{d_n}{d_n^*}\right)^{q_n}}{1 + \left(\frac{d_1}{d_1^*}\right)^{q_1} + \left(\frac{d_2}{d_2^*}\right)^{q_2} + \dots + \left(\frac{d_n}{d_n^*}\right)^{q_n}} \quad (3)$$

We combine the overall response of the behavioral parameter via bilinear interpolation in the nonlinear up- and down-responses U and D :

$$b(\mathbf{u}, \mathbf{d}) = (1 - D) \cdot [(1 - U) \cdot b_0 + U \cdot b_M] + D \cdot b_m \quad (4)$$

Notice that:

- In the presence of a single up-regulating signal u (or a single down-regulating signal d) only, $b(u, d)$ reduces to a Hill response curve $b(u)$ (or $b(d)$) used in systems biology and pharmacodynamics studies.
- Generally, the combined up-regulating signals sets a “target” value of the parameter, which can then be inhibited by the combined down-regulating signals.
- Both U and D vary between 0 and 1 representing the extent of up- and down-regulating signals, respectively. This means that larger values of D represent larger decreases in behavior b .

Note also that adding and removing individual rules does not require alteration to the remaining rules. In this release, we use multi-variate Hill response functions for clarity, but mixed linear and Hill responses could be used in the future. The PhysiCell implementation of this generalized response, additional mathematical details, and expanded examples can be found in [Methods S1](#). Sample multivariate response functions are in [Figures S1](#) and [S3](#).

PhysiCell rules implementation and parameterization. To implement these rules in PhysiCell, users generate a CSV file in which each row is an individual rule and the columns correspond to specific elements of the grammar. The structure of such a row is as follows:

tumor, oxygen, increases, cycle entry, 0.0005, 5.0, 4, 0
cell type signal response behavior maxresponse half-max Hill power applies to dead?

The graphical user interface (GUI) provided by PhysiCell Studio^{56,95,116} simplifies the creation of this CSV in alignment with the framework. Within this GUI, users can also interactively visualize all the rules to assess their sensitivity to different input signals and parameter values.

Our toolset also includes a Python package to analyze PhysiCell models, including sensitivity analysis, calibration, model selection, and validation. These uncertainty quantification (UQ) tasks are critical for understanding how biological and mathematical variability influence model behavior. Importantly, the addition of the grammar framework enables us to offer this to end users without requiring bespoke C++ code or XML parsers. More details on these parameter tuning and parameter sensitivity tools are described in detail in [Methods S1](#). To help drive reproducibility, we generate and save a full description of all rules in HTML and text formats after initial parsing.

Experimental details

Macrophage co-culture with 3D mammary organoids derived from MMTV-PyMT tumors

A previously unpublished replicate image of co-culture of organoids with tumor-associated macrophages is used as the basis of the qualitative behavior of our ABM of macrophage-induced invasion of tumor cells. Experimental methods for the data generated in this figure are described in the original DeNardo et al. publication⁸⁴ describing these findings as follows “Primary nMEC and pMEC pools were established by organoid centrifugation as previously described.¹⁵² Briefly, mammary tissue biopsies were harvested from 76-day-old PyMT female or 12-week-old virgin negative littermates and digested with collagenase A 2.0 mg/ml (Roche) and DNase 2.0 units/ml (Roche) for 2 hr. Organoids were then isolated by differential centrifugation and grown in culture conditions as previously described.¹⁵² Primary nMECs were used within two passages and primary pMEC cells were used within ten passages. Three-dimensional organotypic cultures were established as previously described.¹⁵³ Cultrex basement membrane

extract (BME; R&D Systems) was utilized to limit endotoxin levels. Co-cultures with primary leukocytes were established only after stable organoid structures had formed (approximately 3 weeks for nMEC, 2 weeks for pMEC). Leukocytes were overlaid in medium containing 0.5% BME. Formation of invasive acini was assessed every 12 hr for 3 days. The cytokines IL-4 (20 ng/ml), IL-13 (20 ng/ml), IL-10 (10 ng/ml), IFN γ (5.0 ng/ml) (PeproTech), or LPS (1.0 mM/ml) were added to co-cultures 12 hr after leukocytes overlay. Inhibitors PD153035 (0.1 mM, Calbiochem) or BIBX1382 (10 nM, Calbiochem) were added 1.0 hr prior to the addition of leukocytes. All experiments were repeated two or three times with separate pMEC pools and individual experiments were run at least in triplicate.

Invasion and colony formation assays of gefitinib treated organoids derived from MMTV-PyMT tumors

Primary mammary tumor organoids were isolated from female MMTV-PyMT mice (002374; Jackson Laboratory) using sequential digestion and purification steps as previously described.¹⁵⁴ Briefly, tumors were dissected, divided with a scalpel, and shaken in a collagenase digestion solution for 1 hour at 37 °C. Following digestion, a series of differential centrifugations were used to separate epithelial organoids from stromal cells, with resulting organoids between 100-250 cells in size. For invasion assays, organoids were embedded at a density of 1.2 per μ L into a collagen I extracellular matrix (354236; Corning) in glass bottom imaging plates (662892; Greiner). The ECM was then polymerized for 1 hour at 37 °C, after which DMEM/F-12 media (10565-018; Thermo Fisher) containing 1.0% ITS (51500-056; Thermo Fisher), 1.0% Pen-Strep (P4333; Sigma Aldrich), and 2.5 nM FGF2 (F0291; Sigma Aldrich) was added. Compounds dissolved in DMSO were added after overnight incubation, and assays were then incubated for 96 hours at 37 °C with 5.0% CO₂. Cultures were fixed in 4.0% paraformaldehyde (15714-S; Electron Microscopy Sciences) on day 5 and then imaged on laser scanning confocal microscope equipped with a tunable GaAsp detector, 2k resonant scanner, and LUA-S6 laser unit (AXR; Nikon Instruments). Invasion was assessed by calculating the inverse circularity of each organoid using Nikon NIS-elements software and results are normalized per biological replicate.

For colony formation assays, organoids were further digested to cancer cell clusters (2-10 cells in size) using 1X TryPLE (12604-013; Thermo Fisher). Clusters were then isolated through differential centrifugations as previously described¹⁵⁴ and embedded at a density of 100 per μ L in Matrigel (354230; Corning). After the Matrigel had polymerized, media was added and compounds in DMSO were dosed the following day using a D300e Digital Dispenser (Tecan). The assay was then incubated at 37 °C with 5.0% CO₂ and fixed after 96 hours in 1.0% paraformaldehyde. To determine colony formation, the entire ECM was imaged in 3D, maximum intensity projections were generated, and colonies were counted using custom ImageJ and Python scripts. Percent colony formation was calculated as the number of colonies in each treatment condition normalized to the vehicle control.

Growth and motility of EGF treated MCF10A cells

As described previously,¹⁵⁵ MCF10A cell culture and experimental procedures were conducted based on established methodologies.¹⁵⁶ For routine maintenance and passaging, cells were cultured in a growth medium composed of DMEM/F12 (Invitrogen, #11330-032) supplemented with 5% horse serum (Sigma, #H1138), 20 ng/ml EGF (R&D Systems, #236-EG), 0.5 μ g/ml hydrocortisone (Sigma, #H-4001), 100 ng/ml cholera toxin (Sigma, #C8052), 10 μ g/ml insulin (Sigma, #I9278), and 1% Penicillin/Streptomycin (Invitrogen, #15070-063). For experiments involving EGF perturbation, a growth factor-free medium was prepared using DMEM/F12, 5% horse serum, 0.5 μ g/ml hydrocortisone, 100 ng/ml cholera toxin, and 1% Pen/Strep.

Cells were cultured to 50–80% confluency before being detached with 0.05% trypsin-EDTA (Thermo Fisher Scientific, #25300-054). Subsequently, 20,000 cells were seeded into 24-well plates (Thermo Fisher Scientific, #267062) coated with collagen-1 (Cultrex, #3442-050-01) in growth medium. After six hours, the cells were rinsed with PBS, and the medium was replaced with growth factor-free medium. Following an 18-hour period of growth factor deprivation, cells were treated with either PBS or 10 ng/ml EGF (R&D Systems, #236-EG).

Phenotypic responses to EGF treatment were assessed through live-cell imaging using the Incucyte S3 microscope (Essen BioScience, #4647), which captured images every 30 minutes over a 24-hour period. The dataset includes an Excel spreadsheet that documents the experimental conditions for each imaged well.

PDAC patient-derived tumor spheroid CAF co-culture invasion assay

Samples Acquisition. Patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) were isolated from freshly resected pancreatic ductal adenocarcinoma (PDAC) tumor specimens obtained during pancreatectomy procedures at Johns Hopkins University Hospital. All specimens were processed within 24 hours of surgical resection as previously described for pancreatic cancer organoids.¹⁵⁷ Written informed consent was obtained from all patients prior to sample collection.

Organoid Generation. PDAC tissue samples were rinsed, minced, and digested in a digestion medium containing Dispase (Gibco 17105-041) and Collagenase Type II (Gibco 17101-015) at 37°C for 2–3 hours with 200 rpm shaking. The digested suspension was centrifuged (1500 rpm, 5 minutes, 4°C) and washed multiple times with wash media (DMEM/F-12 supplemented with 1.25 mL Primocin, 5 mL 1M HEPES, 5 mL 100X Glutamax, and 2.5% FBS). Tumoral clusters and single cells were separated from stromal debris and CAFs through differential centrifugation. Organoids were embedded in collagen I gel prepared by mixing collagen I (Corning, rat-tail, 354236) with 10 $\times$ DMEM and 1N NaOH to achieve a final concentration of 3.34 mg/mL. The collagen solution was incubated at 37°C for 60 minutes to allow polymerization before overlaying with growth media containing DMEM/F-12, Primocin, HEPES, Glutamax, EGF (5 ng/mL), insulin (5 μ g/mL), cholera toxin (10 ng/mL), and BSA (0.075%). CAF-containing supernatants were also cultured separately in T75 flasks with RPMI containing 10% FBS. PDO growth was monitored over two weeks to reach an appropriate size, and cultures that failed to expand were discarded.

CAF Media Treatment and Invasion Assays. CAFs were cultured in 2D (T75 flask) and 3D (Matrigel in 24-well plates) environments to induce differentiation into inflammatory (iCAF) and myofibroblast (myCAF) subtypes, respectively. Fibroblast differentiation was validated using qPCR with iCAF and myCAF markers. Once the cells reached 70–80% confluence, the media were replaced with RPMI containing 1% FBS. Conditioned media were collected after 36 hours and used for all 15 PDO cultures. CAF-conditioned media were mixed with PDO growth media at a 1:1 ratio and RPMI with 1% FBS was used as a control. To assess invasion, images of invasive and non-invasive organoids were captured using a Nikon Ti-E inverted microscope at $\times 10$ magnification 72 hours after conditioned media addition. Organoid invasion was quantified by calculating the percentage of PDOs invading collagen fibers and analyzing invasive organoids' circularity using ImageJ software.

Cell motility tracking of PDAC cells and fibroblasts in varying ECM densities, alone and in co-culture

We embedded cells from the hT231 human cancer associated fibroblast cell line and the Panc10.05 pancreatic cancer cell line,¹⁵⁸ either separately or in co-culture, into 3D collagen-I hydrogel and imaged individual cells at five-minute intervals for eight hours. The cell tracking protocol was performed as previously described.⁶⁸ Briefly, the Panc 10.05 and hT231 CAF co-cultures were prepared in type I collagen-based gels that were polymerized for 1 hr in a 37-degree incubator (during which time the gels turned from a liquid to form a stable solid). At the end of the 1 hr polymerization time, the gels are deemed solid/stable and are all gently hydrated with media to keep them porous and feed the cells with nutrients, then placed in the cell culture incubator for approximately 2 hours prior to imaging. The gels (monocultures and co-cultures both) were then loaded onto our microscope and imaged soon after (within 2–3 hours of hydrating), then were run in an overnight movie that elapsed a total time of about 12–16 hours. The trajectories in the .csv files quantified cell movements over either 2.5 hr (30 frame)-long or 8 hr (96 frame)-long trajectories within this 12-hour movie.

Calibration of migration speed in ABM from motility assays

The 3D positions (x, y, z) of each cell—as recorded by the microscope at each timestep—were analyzed, and the motility of each cell was fitted to a trajectory using the anisotropic random walk model described previously,^{68,159} which yields metrics such as average speed ($\mu\text{m/hr}$) for each condition. A protocol for statistical analysis of cell migration in 3D was used to calibrate an anisotropic persistent random walk model.¹⁶⁰ This was performed at each collagen density used in the 2.5 h motility assays. The average speed parameter was taken from this analysis as a function of the collagen density. The combined Hill response (see [Results](#)) is fit to this data. ECM density is used as the increasing signal and the decreasing signal. MATLAB's `fmincon` was used to minimize the sum of square residuals and thus parameterize the Hill responses. The code is available in the GitHub repository associated with this article at https://github.com/PhysiCell-Models/grammar_samples/tree/main/experimental_data_analysis/PancCAFAnalysis.

QUANTIFICATION AND STATISTICAL ANALYSIS

Model initialization from simulated distributions of cellular states and from multi-omics data

Another critical model input is the initialization of the cell types present in an ABM simulation and the initial positions of these cell agents. PhysiCell allows users to initialize cells randomly in the environment or by supplying a user-created file with cell locations. An advantage of the hypothesis grammar is that cellular agents are given human-interpretable names, providing a one-to-one mapping between the agents and cellular labels defined in classical single-cell and spatial molecular analyses. To leverage this mapping and enable data-driven model initialization, we use cell type annotations from bioinformatics datasets to set the relative abundances of the cell types included in our models. If the data also includes spatial coordinates, we use affine linear transformations to position the cells in the simulation domain. By default, the cells are placed to fill the simulation domain while preserving the aspect ratio of the data.

Spatial transcriptomics data of PDAC tumors

We selected two resected pancreatic lesions were subjected to the commercial Visium spatial transcriptomics (ST) sequencing FFPE protocol generated in Bell et al.⁷² to initialize ABMs in this study. Slides were stained with H&E and imaged prior to RNA extraction, and image analysis was performed in parallel with transcriptomic analysis. An artificial intelligence method for annotation of pancreatic tumor tissue regions called CODA¹⁰⁶ was used to annotate acinar cells, islet cells, smooth muscle cells, and the distribution of collagen. This method was also used to distinguish normal ductal, neoplastic, and tumor cells from the H&E imaging, which were further visually confirmed by a pathologist (E.D.T.). Spots with greater than 70% purity of ductal cells were further annotated to assign agent types for the associated tumor and normal cells in each spot. For this annotation, we used our transfer learning method ProjectR¹⁰⁷ version 1.8.0 to distinguish proliferative signaling (modeled as an epithelial phenotype) from co-occurrence of EMT and inflammatory signaling (modeled as the mesenchymal phenotype) as defined in CoGAPS non-negative matrix factorization analysis of in scRNA-seq data PDAC tumors using methods described previously.^{72,108,109} To locate fibroblasts, Seurat version 4.1.0 was used to compute module scores from a pan-CAF gene signature as described previously.⁷² ABM simulations were initialized from these cellular states. In addition, ECM density was initialized using a heuristic from image-derived collagen and cancer-associated fibroblast annotations from the H&E imaging from CODA,¹⁰⁶ and the bounding cells were assumed to contain a similarly dense collagen matrix, forming a niche around the known sample and abstractly reflecting the character of the solid pancreatic tissue. In the ABM, other pancreatic cells in the spatial transcriptomics data were approximated as steady state (no net proliferation, death, motility, or secretion) and were assumed to be essentially inert with regards to carcinogenesis, here primarily modeled in their role as structure

and scaffolding within which the other cell types interact and representing acinar cells, islet cells, and smooth muscle cells. The spatial transcriptomics data^{147,148} are available from GEO as GSE254829.

Deriving a metric to quantify the invasiveness of *in silico* tumor spheroids over time from *in silico* simulation (PhysiCell model output)

Previous studies have quantified the invasiveness of tumor spheroids using microscopy images by assessing the perimeter (contour) of the spheroid and counting cells migrating beyond a defined boundary.^{149,150} These methods were adapted to enable comparison between output from *in silico* PhysiCell models. To quantify invasiveness, the radial distance from the perimeter of the boundary of the simulated tumor volume to the centroid of its contour was calculated. Projections of the spheroid's perimeter extending beyond the median radial distance measured at the initial time point were counted as invasive projections. The total number of invasive projections served as a measure of spheroid invasiveness. Results from simulation experiments of tumor spheroids in PhysiCell were processed and quantified using a custom analytic pipeline¹⁵¹ written in Python (version 3.11). The positions of cells in the ABM at each time point were imported from xml output files produced by PhysiCell as MultiCellDS (MCDS) data structures in Python and used to populate an empty array as individual points. Points were then dilated in the shape of a disk with a gradient of intensity. The simulated outputs contain both images of the secreted factors from fibroblasts, abstracted as an extracellular matrix (ECM) variable, and tumor cells. The locations of the ECM were then imported from the MCDS object, and the amount of ECM present at each voxel in the simulation space was used to derive a contour by projecting onto a 2D mesh. The ECM contour was added to the dilated cells and flattened into a 2D array. Arrays were processed analogously to images of tumor volume, by binarization with an Otsu threshold and segmented to generate a mask. The morphology of mask contours was then quantified to determine the number of invasive projections and determine spheroid invasiveness.

Single-cell RNA-seq of PDAC tumors as a reference dataset to initialize estimates of immune populations in ABM simulations of treatment effects

Simulations of different treatment effects on PDAC in Figure 6 use immune-enriched single-cell RNA-seq data from Stelle et al.⁹² (GSE155698) and with preprocessing to further define immune cell subtypes in reference tumors as described previously.^{67,91} Briefly, to determine the by-tissue cell counts to initialize our simulations, the single-cell RNA sequencing data was preprocessed, clustered, and annotated using the Seurat R package.¹¹⁰ Cell identity clusters of interest ("Activated_CD4", "B cell", "CD4", "CD8", "Effector_CD8", "Epithelial_cancer", "Macrophage", "Mast", "Neutrophil", "NK/CTL", "T cell", "Treg cell") were then thresholded based on median normalized expression of genes of interest (here CD274/PD-L1, PD-1/PD-1, TNFRSF9/CD137) and the number of cells falling into lo/hi categories were reported as described previously.⁹¹ The pre-treatment cell numbers for each immune population were adopted as the baseline count of that agent type, while the number of tumor cells was artificially adjusted to equal 1000, with the relative number of PD-L1^{hi} vs PD-L1^{lo} tumor cells determined by the ratio found in that tissue in the dataset.⁹² Cell-cell communication analysis was performed using the Domino package as described previously by Li et al.⁹¹ to extend the model rules for immune cells to account for their function dependent on CD137 status. We further estimate the relationship of the baseline TME composition on the ABM-simulated therapeutic response with a Pearson correlation computed with the R package ggpubr.

Allen Brain Atlas⁵³ data as a reference dataset to calibrate parameters of an ABM of cortical development

The Allen Brain Atlas⁵³ was used to find z-slices of cortical regions in the mouse brain and the cellularity in each layer to calibrate the model. We selected z-slices that contained sufficient cellularity in the two chosen regions of interest, the somatosensory and auditory cortices. Selecting from each z-slice a rectilinear subset within the target region, we used the Allen Brain Atlas layer annotations to quantify the thickness of each layer.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

This study involved no human subjects, and it developed agent-based simulations that form *in silico* simulations of tumors. All human genomics datasets were taken from prior studies. The PyMT mouse model and MCF10A were used for breast cancer, and patient derived organoids, Panc10.05, and hT231 cell lines were used for pancreatic cancer experimental models. Details of all of these and protocols are described in the experimental methods section of STAR Methods.

Supplemental figures




Figure S1. Multivariate response functions in STAR Methods

Left: a multivariate Hill response function, where s_1 has half-max 2 and Hill power 8, and s_2 has half-max 1 and Hill power 2. Half-maxes are plotted on each variable as blue dashed lines, while the half-max across the multivariate function is plotted as a red contour. $H(s_1)$ and $H(s_2)$ are plotted as black curves along the respective axes.

Right: a multivariate linear response function, where s_1 has min and max thresholds 0.75 and 3.75, and s_2 has thresholds 0 and 2. Half-maxes are plotted on each variable as blue dashed lines, while the half-max across the multivariate function is plotted as a red contour. $L(s_1)$ and $L(s_2)$ are plotted as black curves along the respective axes. Related to [STAR Methods](#).




Figure S2. Converting between linear and Hill response functions, related to STAR Methods

Left: approximating a linear response function (black dotted curve) with a Hill response function (red).

Right: approximating a Hill response function (black dotted) with a linear response function (red).




Figure S3. Sample response functions, related to STAR Methods

Left: the behavioral response function for the statements “oxygen increases cycle entry” and “pressure decreases cycle entry,” using the multivariate Hill response function.

Right: a non-monotonic response function from the statements “ c increases migration bias” (for lower values of c) and “ c decreases migration bias” (for higher values of c), showing both linear and Hill response constructions.




Figure S4. Convergence of QoIs across the replicates in hypoxia model, related to Figure 2

AUC of live (A) and dead (B) non-motile tumor cells. AUC of live (C) and dead (D) motile tumor cells. (E) Wassertein distance of radial distributions between non-motile and motile tumor cells.

Panc10.05 monoculture




Figure S5. PANC10.05 cell motility in monoculture or co-culture, related to Figure 3

Comparing motility behavior of PANC10.05 cells in monoculture or in co-culture with HT-231 CAFs assayed using 30-frame-long trajectories (A–C) and 96-frame-long trajectories (D–F). Average speed ($\mu\text{m}/\text{h}$) (A), average turning angle (degrees/min) (B), and progressivity (C) of PANC10.05 monoculture and co-culture in varying ECM densities. (D–F) equivalent metrics from the 96-frame trajectory experiment.

Panc10.05 in Panc10.05 & HT-231 (CAF) coculture






Figure S6. PANC10.05 cell motility monoculture, related to Figure 3

Motility behavior of PANC10.05 cells in monoculture assayed using 30-frame-long trajectories (A–C) and 96-frame-long trajectories (D–F). Average speed ($\mu\text{m}/\text{h}$) (A), average turning angle (degrees/min) (B), and progressivity (C) of PANC10.05 monoculture in varying ECM densities. (D–F) equivalent metrics from the 96-frame trajectory experiment.

Comparing Panc10.05 in monocultures vs in cocultures

Interesting note - The presence of CAFs seem to increase Panc10.05 speed **except** at the highest of ECM densities (7.0 mg/mL), where it exhibits decreased speed

30 frame-long trajectories
(2.5 hr/trajectory)
n = 4193 total trajectories




(legend on next page)

Figure S7. PANC10.05 cell motility in co-culture, related to [Figure 3](#)

Motility behavior of PANC10.05 cells in co-culture with HT-231 CAFs assayed using 30-frame-long trajectories (A–C) and 96-frame-long trajectories (D–F). Average speed ($\mu\text{m}/\text{h}$) (A), average turning angle (degrees/min) (B), and progressivity (C) of PANC10.05 in co-culture with HT-231 in varying ECM densities. (D–F) equivalent metrics from the 96-frame trajectory experiment.

HT-231 (CAF) monoculture


30 frame-long trajectories
(2.5 hr/trajectory)
 $n = 371$ total trajectories



96 frame-long trajectories
(8 hr/trajectory)
Too few trajectories tracked

HT-231 (CAF) in Panc10.05 & HT-231 (CAF) coculture

30 frame-long trajectories
(2.5 hr/trajectory)
 $n = 142$ total trajectories



96 frame-long trajectories
(8 hr/trajectory)
Too few trajectories tracked

Figure S8. HT-231 CAF motility in monoculture or co-culture, related to [Figure 3](#)

Comparing motility behavior of HT-231 CAFs in monoculture or in co-culture with PANC10.05 cells assayed using 30-frame-long trajectories (A–C) and 96-frame-long trajectories (D–F). Average speed ($\mu\text{m/h}$) (A), average turning angle (degrees/min) (B), and progressivity (C) of HT-231 monoculture and co-culture in varying ECM densities. (D–F) equivalent metrics from the 96-frame trajectory experiment.




Figure S9. Fibroblast and pancreatic cell motility response curves, related to Figure 3

Motility behavior of simulated fibroblasts and pancreatic tumor cells is specified using two Hill curves that come together to fit the experimental data describing the relationship between migration speed and ECM density for each cell type (S5–S8).




Figure S10. Invasiveness of patient-derived organoids, related to Figure 3

(A) Comparison of mean inverse circularity of PDOs between myCAF-conditioned and control media.

(B) Comparison of mean inverse circularity of PDOs between iCAF-conditioned and myCAF-conditioned media.




Figure S11. Local sensitivity analysis of the simple tumor-immune model, related to Figure 4

(A) Simulation of a 5-day evolution using reference parameters.

(B) Area under curve (AUC) for cell populations, extracted from the time course.

(legend continued on next page)

(C) Radial distributions at the final snapshot (day 5) are shown in left plot, while the Wassertein distances extracted from these distributions are presented in the middle plot (macrophages vs. tumor cells) and the right plot (CD8 T cells vs. tumor cells).

(D) Variation in quantities of interest (QoIs) under multiplicative perturbations in the 26D parameter space.

(E) Average and standard deviation of the sensitivity index for each parameter across all QoIs.




Figure S12. Convergence of QoIs across the replicates in simple tumor-immune model, related to Figure 4

AUC of live (A) and dead (B) tumor cells. AUC of pro-inflammatory (C) and anti-inflammatory (D) secretion rate of macrophages. Wasserein distance of radial distributions between tumor cells and macrophages (E) and tumor cells and CD8⁺ T cells (F).




Figure S13. Gefitinib colony formation assay, related to Figure 5

Tumor cells are seeded and the number of successful colonies formed is compared between control and gefitinib (EGFR inhibitor). This shows that inhibiting EGFR signaling does not inhibit colony formation behavior in these tumor cells.




Figure S14. EGF impact on MCF10A proliferation, related to Figure 5
EGF increases MCF10A cell proliferation vs. PBS control over a 24-h time frame.




Figure S15. Simulated tumor cell growth under therapy combinations vs. untreated virtual control, related to Figure 6
Time series of simulated tumor cell counts under baseline and combination therapy conditions for PDAC tissues 1–8.




Figure S16. Simulated tumor cell growth under treatment and control for PDAC tissues 9–16, related to Figure 6
Time series of simulated tumor cell counts under baseline and combination therapy conditions for PDAC tissues 9–16.




Figure S17. Simulated tissue endpoints under single- and triple-combination treatments and virtual control, related to Figure 6
Snapshots of agents at simulation endpoints for each tissue, baseline, single therapies, and triple-combination therapy shown.





Figure S18. Simulated tissue endpoints under double-combination treatments, related to Figure 6
Snapshots of agents at simulation endpoints for each tissue, double-combination therapies shown.



(legend on next page)

Figure S19. Waterfall plots of treatment efficacy for simulated tissue, related to [Figure 6](#)

Waterfall plots showing efficacy of each simulated therapy in each tissue. Positive values indicated tumor grew relative to baseline final volume; negative values indicate tumor shrinkage.

Therapy: GVAX + ICI + URU

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue




Figure S20. Immune cell abundances in GVAX + ICI + URU treatment, related to Figure 6

Immune population abundances in tissues, binned by whether the simulation with GVAX + ICI + URU reached the tumor clearance threshold. Macrophage abundance was significantly higher in tissues whose simulations reached the tumor clearance threshold.

Therapy: GVAX

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue

no tissues met the threshold of 50% tumor volume reduction relative to baseline




Figure S21. Immune cell abundances in GVAX treatment, related to Figure 6

Shown here is the abundance of macrophages and CD4 and CD8 T cells in each tissue. With the GVAX treatment, no tissues reached the threshold of 50% clearance relative to baseline.

Therapy: ICI

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue
(not enough observations in "true" for t test)




Figure S22. Immune cell abundances in ICI treatment, related to Figure 6

Immune population abundances in tissues, binned by whether the simulation with immune checkpoint inhibitor (ICI, Nivolumab) reached the tumor clearance threshold. Not enough tissues met the clearance threshold for significance test.

Therapy: GVAX+ICI

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue




Figure S23. Immune cell abundances in GVAX + ICI treatment, related to Figure 6

Boxplots comparing baseline immune population abundances in each tissue simulation with efficacy of GVAX + ICI, contrasting tissues that grew relative to baseline vs. those that shrank (threshold = TRUE means the relative tumor volume change is < -0.5 or the tumor shrank; FALSE is the opposite, tumor growth did not meet our threshold).

Therapy: URU

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue




Figure S24. Immune cell abundances in URU treatment, related to Figure 6

Immune population abundances in tissues, binned by whether the simulation with CD137 agonist (Urelemb/URU) reached the tumor clearance threshold. None of these comparisons were significant.

Therapy: GVAX+URU

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue




Figure S25. Immune cell abundances in GVAX + URU treatment, related to Figure 6

Immune population abundances in tissues, binned by whether the simulation with GVAX + URU reached the tumor clearance threshold. None of these comparisons were significant.

Therapy: ICI + URU

compare baseline immune population abundances to therapeutic efficacy in each simulated tissue




Figure S26. Immune cell abundances in ICI + URU treatment, related to Figure 6

Immune population abundances in tissues, binned by whether the simulation with ICI + URU reached the tumor clearance threshold. None of these comparisons were significant.